[
  {
    "Index": "0",
    "Results": [
      {
        "bel_statement": "a(CHEBI:6801) hasComponent a(CHEBI:59990)",
        "evidence": "Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA)."
      },
      {
        "bel_statement": "a(CHEBI:23888) increases a(EFO:0004368)",
        "evidence": "Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules."
      },
      {
        "bel_statement": "a(CHEBI:23888) challenges a(EFO:0011061)",
        "evidence": "Therefore, purity and toxicity are also a big challenge for drug discovery and development."
      },
      {
        "bel_statement": "p(HGNC:11037) hasActivity a(CHEBI:71196)",
        "evidence": "Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors."
      },
      {
        "bel_statement": "p(HGNC:11037) hasActivity a(CHEBI:68612)",
        "evidence": "Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D010361",
        "entry_name": "Patients"
      },
      {
        "db": "MESH",
        "id": "D055808",
        "entry_name": "Drug Discovery"
      },
      {
        "db": "MESH",
        "id": "D008722",
        "entry_name": "Methods"
      },
      {
        "db": "EFO",
        "id": "0004368",
        "entry_name": "Number of molecules"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:6801",
        "entry_name": "metformin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:143130",
        "entry_name": "impurity"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17170",
        "entry_name": "dimethylamine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:59990",
        "entry_name": "N,N-dimethyl-4-nitrosoaniline"
      },
      {
        "db": "EFO",
        "id": "0011061",
        "entry_name": "toxicity"
      },
      {
        "db": "MESH",
        "id": "D055808",
        "entry_name": "Drug Discovery"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:71196",
        "entry_name": "glucagon-like peptide-1 receptor agonist"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:68612",
        "entry_name": "EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor"
      },
      {
        "db": "MESH",
        "id": "D012108",
        "entry_name": "Research Personnel"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25367",
        "entry_name": "molecule"
      }
    ]
  },
  {
    "Index": "1",
    "Results": [
      {
        "bel_statement": "bp(GO:0030073) decreases a(HGNC:INS)",
        "evidence": "It could be caused by a decrease in pancreatic cell insulin secretion or a lack of insulin responsiveness in the body."
      },
      {
        "bel_statement": "a(HGNC:INS) decreases a(MESH:D001786)",
        "evidence": "Insulin aids glucose assimilation within cells, allowing blood glucose levels to remain within a healthy range (80-120 mg/dL)."
      },
      {
        "bel_statement": "a(HGNC:INS) decreases path(MESH:D006943)",
        "evidence": "Thus, a deficit of insulin in the body results in hyperglycemia, raising the blood glucose level, which in turn leads to many metabolic and life-threatening complications, including cardiovascular, nephropathic, and neuropathic diseases, amongst others."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003882",
        "entry_name": "Dermatomyositis"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "HP",
        "id": "HP:0003676",
        "entry_name": "Progressive"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "EFO",
        "id": "0002966",
        "entry_name": "pancreatic cell"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D000163",
        "entry_name": "Acquired Immunodeficiency Syndrome"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D001786",
        "entry_name": "Blood Glucose"
      },
      {
        "db": "HP",
        "id": "HP:0032322",
        "entry_name": "Healthy"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "MESH",
        "id": "D001786",
        "entry_name": "Blood Glucose"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      }
    ]
  },
  {
    "Index": "2",
    "Results": [
      {
        "bel_statement": "path(MESH:D003920) positiveCorrelation path(MESH:D009765)",
        "evidence": "According to an International Diabetes Federation (IDF) report, the Federated States of Micronesia (Micronesia) have the world's most overweight population, with a 30% obesity prevalence."
      },
      {
        "bel_statement": "path(MESH:D003920) positiveCorrelation a(MESH:D004032)",
        "evidence": "Approximately 425 million people worldwide are affected by diabetes, and this is projected to increase to ~629 million by the year 2045 due to unhealthy diets and inactive lifestyles."
      },
      {
        "bel_statement": "path(MESH:D003920) positiveCorrelation a(MESH:D008019)",
        "evidence": "Approximately 425 million people worldwide are affected by diabetes, and this is projected to increase to ~629 million by the year 2045 due to unhealthy diets and inactive lifestyles."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D011153",
        "entry_name": "Population"
      },
      {
        "db": "HP",
        "id": "HP:0032320",
        "entry_name": "Affected"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003882",
        "entry_name": "Dermatomyositis"
      },
      {
        "db": "EFO",
        "id": "0000246",
        "entry_name": "age"
      },
      {
        "db": "MESH",
        "id": "D011153",
        "entry_name": "Population"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D008849",
        "entry_name": "Micronesia"
      },
      {
        "db": "MESH",
        "id": "D008849",
        "entry_name": "Micronesia"
      },
      {
        "db": "MESH",
        "id": "D050177",
        "entry_name": "Overweight"
      },
      {
        "db": "MESH",
        "id": "D011153",
        "entry_name": "Population"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "MESH",
        "id": "D015995",
        "entry_name": "Prevalence"
      },
      {
        "db": "MESH",
        "id": "D017691",
        "entry_name": "Caribbean Region"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D000368",
        "entry_name": "Aged"
      },
      {
        "db": "MESH",
        "id": "D015995",
        "entry_name": "Prevalence"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D001213",
        "entry_name": "Asian"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D015995",
        "entry_name": "Prevalence"
      },
      {
        "db": "MESH",
        "id": "D008436",
        "entry_name": "Mauritius"
      },
      {
        "db": "MESH",
        "id": "D013188",
        "entry_name": "Sri Lanka"
      },
      {
        "db": "MESH",
        "id": "D007194",
        "entry_name": "India"
      },
      {
        "db": "HP",
        "id": "HP:0032320",
        "entry_name": "Affected"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D008019",
        "entry_name": "Life Style"
      }
    ]
  },
  {
    "Index": "3",
    "Results": [
      {
        "bel_statement": "bp(EFO:0003940) decreases path(MESH:D003920)",
        "evidence": "In the case of Micronesia and other nearby islands, there is one hypothesis that argues the cause of severe diabetes is inadequate physical activity and an unhealthy diet."
      },
      {
        "bel_statement": "a(MESH:D000073893) increases path(MESH:D003920)",
        "evidence": "During times in which there is an inadequate food supply, people in Micronesia consume an excess amount of sugar to sustain themselves."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D008849",
        "entry_name": "Micronesia"
      },
      {
        "db": "MESH",
        "id": "D062312",
        "entry_name": "Islands"
      },
      {
        "db": "HP",
        "id": "HP:0012828",
        "entry_name": "Severe"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "EFO",
        "id": "0003940",
        "entry_name": "physical activity"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D005523",
        "entry_name": "Food Supply"
      },
      {
        "db": "MESH",
        "id": "D008849",
        "entry_name": "Micronesia"
      },
      {
        "db": "MESH",
        "id": "D000073893",
        "entry_name": "Sugars"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:33290",
        "entry_name": "food"
      },
      {
        "db": "MESH",
        "id": "D000073893",
        "entry_name": "Sugars"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D006184",
        "entry_name": "Habits"
      },
      {
        "db": "MESH",
        "id": "D011153",
        "entry_name": "Population"
      },
      {
        "db": "MESH",
        "id": "D050177",
        "entry_name": "Overweight"
      }
    ]
  },
  {
    "Index": "4",
    "Results": [
      {
        "bel_statement": "bp(EFO:0003940) increases bp(GO:0042593)",
        "evidence": "Correspondingly, increased physical activity has been shown to help maintain glucose homeostasis in the body and to delay the onset of impaired glucose tolerance."
      },
      {
        "bel_statement": "bp(EFO:0003940) decreases path(HP:0040270)",
        "evidence": "Correspondingly, increased physical activity has been shown to help maintain glucose homeostasis in the body and to delay the onset of impaired glucose tolerance."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003882",
        "entry_name": "Dermatomyositis"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D020500",
        "entry_name": "Statistics"
      },
      {
        "db": "MESH",
        "id": "D020500",
        "entry_name": "Statistics"
      },
      {
        "db": "MESH",
        "id": "D020501",
        "entry_name": "Tables"
      },
      {
        "db": "MESH",
        "id": "D007194",
        "entry_name": "India"
      },
      {
        "db": "MESH",
        "id": "D015995",
        "entry_name": "Prevalence"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D006296",
        "entry_name": "Health Services"
      },
      {
        "db": "MESH",
        "id": "D011153",
        "entry_name": "Population"
      },
      {
        "db": "MESH",
        "id": "D006184",
        "entry_name": "Habits"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "EFO",
        "id": "0003940",
        "entry_name": "physical activity"
      },
      {
        "db": "MESH",
        "id": "D057185",
        "entry_name": "Sedentary Behavior"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "EFO",
        "id": "0003940",
        "entry_name": "physical activity"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "MESH",
        "id": "D017668",
        "entry_name": "Age of Onset"
      },
      {
        "db": "HP",
        "id": "HP:0040270",
        "entry_name": "Impaired glucose tolerance"
      }
    ]
  },
  {
    "Index": "5",
    "Results": [
      {
        "bel_statement": "path(MESH:D003920) isA path(MESH:D002965)",
        "evidence": "Classification of Diabetes Mellitus"
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D002965",
        "entry_name": "Classification"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "6",
    "Results": [
      {
        "bel_statement": "a(MESH:D003920) positiveCorrelation a(HP:0100515)",
        "evidence": "The term diabetes (to siphon or to pass through, in Greek) was first used by Apollonius of Memphis, who noted that patients with diabetes present with frequent urination."
      },
      {
        "bel_statement": "a(MESH:D003920) positiveCorrelation a(MESH:D006029)",
        "evidence": "A Greek physician, Galen, hypothesized it to be a type of kidney disease, as the most prominent symptom was glucosuria."
      },
      {
        "bel_statement": "a(MESH:D003920) positiveCorrelation a(MESH:D001786)",
        "evidence": "Later in the 19th century, Matthew Dobson discovered that the excessive amount of sugar in the urine of patients with diabetes gives it that sweet taste."
      },
      {
        "bel_statement": "a(MESH:D003920) positiveCorrelation a(MESH:D001786)",
        "evidence": "Banting and Macleod observed a reduction in blood glucose levels after administering islets of Langerhans to a pancreatectomized dog, and for this breakthrough discovery they were awarded the Nobel Prize in 1923."
      },
      {
        "bel_statement": "a(HGNC:6081) decreases a(MESH:D001786)",
        "evidence": "Banting and Macleod observed a reduction in blood glucose levels after administering islets of Langerhans to a pancreatectomized dog, and for this breakthrough discovery they were awarded the Nobel Prize in 1923."
      },
      {
        "bel_statement": "a(HGNC:6081) decreases a(MESH:D003920)",
        "evidence": "Gradually, by the late 20th century, as the mechanisms behind diabetes started to unfold, various insulin preparations and other oral hypoglycemic drugs paved their way onto the market."
      },
      {
        "bel_statement": "a(CHEBI:35526) decreases a(MESH:D003920)",
        "evidence": "Gradually, by the late 20th century, as the mechanisms behind diabetes started to unfold, various insulin preparations and other oral hypoglycemic drugs paved their way onto the market."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D035583",
        "entry_name": "Rare Diseases"
      },
      {
        "db": "MESH",
        "id": "D015431",
        "entry_name": "Weight Loss"
      },
      {
        "db": "HP",
        "id": "HP:0100515",
        "entry_name": "Pollakisuria"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HP",
        "id": "HP:0100515",
        "entry_name": "Pollakisuria"
      },
      {
        "db": "MESH",
        "id": "D010820",
        "entry_name": "Physicians"
      },
      {
        "db": "MESH",
        "id": "D007674",
        "entry_name": "Kidney Diseases"
      },
      {
        "db": "MESH",
        "id": "D006029",
        "entry_name": "Glycosuria"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D011642",
        "entry_name": "Publications"
      },
      {
        "db": "MESH",
        "id": "D008511",
        "entry_name": "Medicine"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D014556",
        "entry_name": "Urine"
      },
      {
        "db": "MESH",
        "id": "D003116",
        "entry_name": "Color"
      },
      {
        "db": "MESH",
        "id": "D013649",
        "entry_name": "Taste"
      },
      {
        "db": "MESH",
        "id": "D013649",
        "entry_name": "Taste"
      },
      {
        "db": "MESH",
        "id": "D010361",
        "entry_name": "Patients"
      },
      {
        "db": "MESH",
        "id": "D014556",
        "entry_name": "Urine"
      },
      {
        "db": "HGNC",
        "id": "34499",
        "entry_name": "SMIM10L2A"
      },
      {
        "db": "MESH",
        "id": "D009275",
        "entry_name": "Names"
      },
      {
        "db": "MESH",
        "id": "D006722",
        "entry_name": "Honey"
      },
      {
        "db": "MESH",
        "id": "D000073893",
        "entry_name": "Sugars"
      },
      {
        "db": "MESH",
        "id": "D014556",
        "entry_name": "Urine"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D013649",
        "entry_name": "Taste"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D001786",
        "entry_name": "Blood Glucose"
      },
      {
        "db": "MESH",
        "id": "D007515",
        "entry_name": "Islets of Langerhans"
      },
      {
        "db": "MESH",
        "id": "D004285",
        "entry_name": "Dogs"
      },
      {
        "db": "MESH",
        "id": "D009613",
        "entry_name": "Nobel Prize"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      }
    ]
  },
  {
    "Index": "7",
    "Results": [
      {
        "bel_statement": "a(HGNC:INS) decreases path(MESH:D003920)",
        "evidence": "At present, based on insulin deficiency and insensitivity of cells towards insulin, diabetes is classified into three major types, described below."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D002965",
        "entry_name": "Classification"
      },
      {
        "db": "MESH",
        "id": "D002965",
        "entry_name": "Classification"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "8",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "9",
    "Results": [
      {
        "bel_statement": "a(MESH:\"Immune System\") directlyDecreases a(MESH:\"Insulin-Secreting Cells\")",
        "evidence": "T1DM is primarily caused by the destruction of pancreatic beta-cells by the body's immune system and is also known as Insulin Dependent Diabetes Mellitus."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "MESH",
        "id": "D007107",
        "entry_name": "Immune System"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D015995",
        "entry_name": "Prevalence"
      },
      {
        "db": "MESH",
        "id": "D002648",
        "entry_name": "Child"
      }
    ]
  },
  {
    "Index": "10",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "11",
    "Results": [
      {
        "bel_statement": "a(MESH:D050177) increases a(EFO:0002614)",
        "evidence": "Being overweight or obese is a major risk factor for T2DM, as it may increase the likelihood of insulin resistance."
      },
      {
        "bel_statement": "a(EFO:0002614) decreases a(CHEBI:17234)",
        "evidence": "This in turn will decrease uptake of glucose in, for example, the heart or musculoskeletal tissues, with simultaneous increase in glucose production in organs such as the liver."
      },
      {
        "bel_statement": "a(EFO:0002614) increases a(CHEBI:17234)",
        "evidence": "This in turn will decrease uptake of glucose in, for example, the heart or musculoskeletal tissues, with simultaneous increase in glucose production in organs such as the liver."
      },
      {
        "bel_statement": "bp(GO:0030073) increases a(HGNC:6081)",
        "evidence": "To counter this, insulin secretion is enhanced by beta-cells."
      },
      {
        "bel_statement": "a(EFO:0002614) increases a(MESH:D006943)",
        "evidence": "Therefore, hyperglycemia and hyperinsulinemia often coexist during early T2DM."
      },
      {
        "bel_statement": "a(EFO:0002614) increases a(MESH:D006946)",
        "evidence": "Therefore, hyperglycemia and hyperinsulinemia often coexist during early T2DM."
      },
      {
        "bel_statement": "a(EFO:1001905) regulates a(HP:0006279)",
        "evidence": "Some of the factors that control beta-cell functioning include oxidative stress, ER-stress and autophagy."
      },
      {
        "bel_statement": "bp(GO:0006914) regulates a(HP:0006279)",
        "evidence": "Some of the factors that control beta-cell functioning include oxidative stress, ER-stress and autophagy."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D003924",
        "entry_name": "Diabetes Mellitus, Type 2"
      },
      {
        "db": "MESH",
        "id": "D003924",
        "entry_name": "Diabetes Mellitus, Type 2"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003924",
        "entry_name": "Diabetes Mellitus, Type 2"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HP",
        "id": "HP:0006279",
        "entry_name": "Beta-cell dysfunction"
      },
      {
        "db": "MESH",
        "id": "D050177",
        "entry_name": "Overweight"
      },
      {
        "db": "DOID",
        "id": "DOID:9970",
        "entry_name": "obesity"
      },
      {
        "db": "MESH",
        "id": "D012307",
        "entry_name": "Risk Factors"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D006321",
        "entry_name": "Heart"
      },
      {
        "db": "MESH",
        "id": "D014024",
        "entry_name": "Tissues"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:38960",
        "entry_name": "terbufos"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "MESH",
        "id": "D006946",
        "entry_name": "Hyperinsulinism"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "EFO",
        "id": "1001905",
        "entry_name": "oxidative stress"
      },
      {
        "db": "GO",
        "id": "GO:0006914",
        "entry_name": "autophagy"
      },
      {
        "db": "MESH",
        "id": "D012108",
        "entry_name": "Research Personnel"
      },
      {
        "db": "HP",
        "id": "HP:0012826",
        "entry_name": "Moderate"
      },
      {
        "db": "MESH",
        "id": "D017668",
        "entry_name": "Age of Onset"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      }
    ]
  },
  {
    "Index": "12",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D016640",
        "entry_name": "Diabetes, Gestational"
      },
      {
        "db": "MESH",
        "id": "D016640",
        "entry_name": "Diabetes, Gestational"
      }
    ]
  },
  {
    "Index": "13",
    "Results": [
      {
        "bel_statement": "path(MESH:D016640) increases path(MESH:D003920)",
        "evidence": "Mothers with GDM are at increased risk for the development of T2DM after pregnancy."
      },
      {
        "bel_statement": "path(MESH:D016640) increases path(MESH:D009765)",
        "evidence": "Their offspring have increased rates of birth trauma, as well as a higher chance of developing issues with obesity and diabetes later in life."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D009035",
        "entry_name": "Mothers"
      },
      {
        "db": "MESH",
        "id": "D016640",
        "entry_name": "Diabetes, Gestational"
      },
      {
        "db": "MESH",
        "id": "D018149",
        "entry_name": "Glucose Intolerance"
      },
      {
        "db": "MESH",
        "id": "D011247",
        "entry_name": "Pregnancy"
      },
      {
        "db": "MESH",
        "id": "D000339",
        "entry_name": "Affect"
      },
      {
        "db": "MESH",
        "id": "D037841",
        "entry_name": "Pregnant Women"
      },
      {
        "db": "MESH",
        "id": "D009035",
        "entry_name": "Mothers"
      },
      {
        "db": "MESH",
        "id": "D016640",
        "entry_name": "Diabetes, Gestational"
      },
      {
        "db": "EFO",
        "id": "0005847",
        "entry_name": "increased risk"
      },
      {
        "db": "MESH",
        "id": "D011247",
        "entry_name": "Pregnancy"
      },
      {
        "db": "GO",
        "id": "GO:0007567",
        "entry_name": "parturition"
      },
      {
        "db": "MESH",
        "id": "D014947",
        "entry_name": "Wounds and Injuries"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D019369",
        "entry_name": "Life"
      },
      {
        "db": "MESH",
        "id": "D009035",
        "entry_name": "Mothers"
      },
      {
        "db": "MESH",
        "id": "D016640",
        "entry_name": "Diabetes, Gestational"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "EFO",
        "id": "0000483",
        "entry_name": "exercise"
      }
    ]
  },
  {
    "Index": "14",
    "Results": [
      {
        "bel_statement": "a(CHEBI:35526) isA a(CHEBI:23888)",
        "evidence": "Common Targets for Anti-Diabetic Drug"
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      }
    ]
  },
  {
    "Index": "15",
    "Results": [
      {
        "bel_statement": "a(HGNC:INS) increases a(MESH:Tissues)",
        "evidence": "Several studies have reported compounds that improved insulin's action on target tissues and helped restore beta-cell function."
      },
      {
        "bel_statement": "a(CHEBI:90415) increases a(HGNC:INS)",
        "evidence": "Among these, four major target types are known as insulin secretagogues, insulin mimickers and sensitizers, and starch blockers."
      },
      {
        "bel_statement": "a(CHEBI:139492) increases a(HGNC:INS)",
        "evidence": "Among these, four major target types are known as insulin secretagogues, insulin mimickers and sensitizers, and starch blockers."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D008019",
        "entry_name": "Life Style"
      },
      {
        "db": "HP",
        "id": "HP:0032320",
        "entry_name": "Affected"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "GO",
        "id": "GO:0001897",
        "entry_name": "cytolysis by symbiont of host cells"
      },
      {
        "db": "HGNC",
        "id": "18549",
        "entry_name": "DCSTAMP"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "MESH",
        "id": "D014024",
        "entry_name": "Tissues"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:90415",
        "entry_name": "insulin secretagogue"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:139492",
        "entry_name": "sensitiser"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28017",
        "entry_name": "starch"
      }
    ]
  },
  {
    "Index": "16",
    "Results": [],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:90415",
        "entry_name": "insulin secretagogue"
      }
    ]
  },
  {
    "Index": "17",
    "Results": [
      {
        "bel_statement": "a(CHEBI:90415) increases sec(p(HGNC:INS))",
        "evidence": "Insulin secretagogues work by stimulating beta-cells to secrete more insulin."
      },
      {
        "bel_statement": "a(CHEBI:26831) increases sec(p(HGNC:INS))",
        "evidence": "Sulphonylureas (SU) bind to the sulphonylurea receptors on pancreatic beta-cells and stimulate them to secrete insulin."
      },
      {
        "bel_statement": "a(CHEBI:26831) decreases a(MESH:D006442)",
        "evidence": "SU have shown good efficacy in reducing glycated hemoglobin microvasculature complications in patients with T2DM."
      },
      {
        "bel_statement": "a(CHEBI:90415) increases a(GO:0008152)",
        "evidence": "Jean-Claude Henquin proposed five potential action sites for insulin secretagogue beta-cell metabolism activation."
      },
      {
        "bel_statement": "a(CHEBI:90415) increases a(MESH:D054086)",
        "evidence": "Increased blocking of beta-cell KATP channels."
      },
      {
        "bel_statement": "a(CHEBI:90415) increases a(CHEBI:29108)",
        "evidence": "Increase in intracellular (Ca2+) concentration by means other than KATP channels."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:90415",
        "entry_name": "insulin secretagogue"
      },
      {
        "db": "MESH",
        "id": "D014937",
        "entry_name": "Work"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26831",
        "entry_name": "N,N''-sulfonyldiurea"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D006442",
        "entry_name": "Glycated Hemoglobin"
      },
      {
        "db": "HP",
        "id": "HP:0025297",
        "entry_name": "Prolonged"
      },
      {
        "db": "HP",
        "id": "HP:0025297",
        "entry_name": "Prolonged"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:90415",
        "entry_name": "insulin secretagogue"
      },
      {
        "db": "GO",
        "id": "GO:0008152",
        "entry_name": "metabolic process"
      },
      {
        "db": "MESH",
        "id": "D054086",
        "entry_name": "KATP Channels"
      },
      {
        "db": "GO",
        "id": "GO:0005622",
        "entry_name": "intracellular anatomical structure"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:29108",
        "entry_name": "calcium(2+)"
      },
      {
        "db": "MESH",
        "id": "D054086",
        "entry_name": "KATP Channels"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      }
    ]
  },
  {
    "Index": "18",
    "Results": [
      {
        "bel_statement": "a(CHEBI:CHEBI:139492) increases p(HGNC:INS)",
        "evidence": "Insulin mimickers and sensitizers can enhance the activity of insulin."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:139492",
        "entry_name": "sensitiser"
      }
    ]
  },
  {
    "Index": "19",
    "Results": [
      {
        "bel_statement": "a(CHEBI:139492) increases act(p(HGNC:6081))",
        "evidence": "Insulin mimickers and sensitizers are agents which are helpful in lowering blood-glucose levels and are usually found as dietary supplements. They work by activating glucose transporters on muscle and fat cells, thus mimicking the function of insulin."
      },
      {
        "bel_statement": "a(CHEBI:50864) increases act(p(HGNC:6081))",
        "evidence": "Insulin sensitizers work by increasing the sensitivity of body tissues towards insulin."
      },
      {
        "bel_statement": "a(CHEBI:50864) decreases bp(GO:0007596)",
        "evidence": "A variety of observable cardiac risk factors such as an increased risk of blood clotting, elevated blood pressure, lipid profile or C-reactive protein, undesired lipoprotein(a) or serum fibrinogen, and even abnormal thickening of the heart muscle have also been shown to improve upon use of insulin sensitizers."
      },
      {
        "bel_statement": "a(CHEBI:50864) decreases a(HGNC:2367)",
        "evidence": "A variety of observable cardiac risk factors such as an increased risk of blood clotting, elevated blood pressure, lipid profile or C-reactive protein, undesired lipoprotein(a) or serum fibrinogen, and even abnormal thickening of the heart muscle have also been shown to improve upon use of insulin sensitizers."
      },
      {
        "bel_statement": "a(CHEBI:50864) decreases a(HGNC:6667)",
        "evidence": "A variety of observable cardiac risk factors such as an increased risk of blood clotting, elevated blood pressure, lipid profile or C-reactive protein, undesired lipoprotein(a) or serum fibrinogen, and even abnormal thickening of the heart muscle have also been shown to improve upon use of insulin sensitizers."
      },
      {
        "bel_statement": "a(CHEBI:50864) decreases a(FPLX:Fibrinogen)",
        "evidence": "A variety of observable cardiac risk factors such as an increased risk of blood clotting, elevated blood pressure, lipid profile or C-reactive protein, undesired lipoprotein(a) or serum fibrinogen, and even abnormal thickening of the heart muscle have also been shown to improve upon use of insulin sensitizers."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:139492",
        "entry_name": "sensitiser"
      },
      {
        "db": "MESH",
        "id": "D019587",
        "entry_name": "Dietary Supplements"
      },
      {
        "db": "MESH",
        "id": "D014937",
        "entry_name": "Work"
      },
      {
        "db": "FPLX",
        "id": "SLC2A",
        "entry_name": "SLC2A"
      },
      {
        "db": "MESH",
        "id": "D009132",
        "entry_name": "Muscles"
      },
      {
        "db": "MESH",
        "id": "D017667",
        "entry_name": "Adipocytes"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50864",
        "entry_name": "insulin-sensitizing drug"
      },
      {
        "db": "MESH",
        "id": "D014937",
        "entry_name": "Work"
      },
      {
        "db": "MESH",
        "id": "D014024",
        "entry_name": "Tissues"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D012307",
        "entry_name": "Risk Factors"
      },
      {
        "db": "EFO",
        "id": "0005847",
        "entry_name": "increased risk"
      },
      {
        "db": "GO",
        "id": "GO:0007596",
        "entry_name": "blood coagulation"
      },
      {
        "db": "MESH",
        "id": "D001794",
        "entry_name": "Blood Pressure"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18059",
        "entry_name": "lipid"
      },
      {
        "db": "HGNC",
        "id": "2367",
        "entry_name": "CRP"
      },
      {
        "db": "HGNC",
        "id": "6667",
        "entry_name": "LPA"
      },
      {
        "db": "MESH",
        "id": "D044967",
        "entry_name": "Serum"
      },
      {
        "db": "FPLX",
        "id": "Fibrinogen",
        "entry_name": "Fibrinogen"
      },
      {
        "db": "MESH",
        "id": "D009206",
        "entry_name": "Myocardium"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50864",
        "entry_name": "insulin-sensitizing drug"
      }
    ]
  },
  {
    "Index": "20",
    "Results": [],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:28017",
        "entry_name": "starch"
      }
    ]
  },
  {
    "Index": "21",
    "Results": [
      {
        "bel_statement": "a(CHEBI:67239) decreases a(CHEBI:16646)",
        "evidence": "Another important class is alpha-glucosidase inhibitors, which act by slowing down carbohydrate absorption."
      },
      {
        "bel_statement": "a(CHEBI:80270) increases bp(GO:0030073)",
        "evidence": "It works by delaying gastric emptying, increasing insulin secretion, and reducing glucagon secretion."
      },
      {
        "bel_statement": "a(CHEBI:80270) decreases bp(GO:0070091)",
        "evidence": "It works by delaying gastric emptying, increasing insulin secretion, and reducing glucagon secretion."
      },
      {
        "bel_statement": "a(CHEBI:80270) decreases bp(GO:0035483)",
        "evidence": "It works by delaying gastric emptying, increasing insulin secretion, and reducing glucagon secretion."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:67239",
        "entry_name": "EC 3.2.1.20 (alpha-glucosidase) inhibitor"
      },
      {
        "db": "HGNC",
        "id": "16",
        "entry_name": "SERPINA3"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:16646",
        "entry_name": "carbohydrate"
      },
      {
        "db": "MESH",
        "id": "D000042",
        "entry_name": "Absorption"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D020909",
        "entry_name": "Acarbose"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:6935",
        "entry_name": "Miglitol"
      },
      {
        "db": "HGNC",
        "id": "3009",
        "entry_name": "DPP4"
      },
      {
        "db": "HGNC",
        "id": "3009",
        "entry_name": "DPP4"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "HGNC",
        "id": "16",
        "entry_name": "SERPINA3"
      },
      {
        "db": "GO",
        "id": "GO:0005975",
        "entry_name": "carbohydrate metabolic process"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:80270",
        "entry_name": "Glucagon-like peptide 1"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "MESH",
        "id": "D062407",
        "entry_name": "Meals"
      },
      {
        "db": "MESH",
        "id": "D000273",
        "entry_name": "Adipose Tissue"
      },
      {
        "db": "GO",
        "id": "GO:0035483",
        "entry_name": "gastric emptying"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "GO",
        "id": "GO:0070091",
        "entry_name": "glucagon secretion"
      }
    ]
  },
  {
    "Index": "22",
    "Results": [
      {
        "bel_statement": "a(CHEBI:85078) increases bp(GO:0007588)",
        "evidence": "Canagliflozin and dapagliflozin are recently approved drugs in this category. These agents promote glucose excretion by the kidney and thus exert their actions independent of insulin."
      },
      {
        "bel_statement": "a(MESH:D000068896) increases bp(GO:0007588)",
        "evidence": "Canagliflozin and dapagliflozin are recently approved drugs in this category. These agents promote glucose excretion by the kidney and thus exert their actions independent of insulin."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D027981",
        "entry_name": "Symporters"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "MESH",
        "id": "D000068896",
        "entry_name": "Canagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85078",
        "entry_name": "dapagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "GO",
        "id": "GO:0007588",
        "entry_name": "excretion"
      },
      {
        "db": "MESH",
        "id": "D007668",
        "entry_name": "Kidney"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      }
    ]
  },
  {
    "Index": "23",
    "Results": [
      {
        "bel_statement": "a(CHEBI:23888) decreases path(MESH:D006943)",
        "evidence": "The other advantages of these drugs include modest weight loss and a low risk of hyperglycemia, etc.."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D015431",
        "entry_name": "Weight Loss"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25367",
        "entry_name": "molecule"
      },
      {
        "db": "MESH",
        "id": "D016430",
        "entry_name": "Clinical Trial"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D016430",
        "entry_name": "Clinical Trial"
      },
      {
        "db": "MESH",
        "id": "D020501",
        "entry_name": "Tables"
      }
    ]
  },
  {
    "Index": "24",
    "Results": [],
    "annotations": []
  },
  {
    "Index": "25",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D042842",
        "entry_name": "11-beta-Hydroxysteroid Dehydrogenases"
      }
    ]
  },
  {
    "Index": "26",
    "Results": [
      {
        "bel_statement": "a(CHEBI:16962) increases a(CHEBI:17650)",
        "evidence": "11beta-Hydroxysteroid dehydrogenase is an enzyme that catalyzes the conversion of inactive cortisone to active cortisol."
      },
      {
        "bel_statement": "a(CHEBI:17650) increases path(MESH:D003920)",
        "evidence": "Literature reports indicated that high circulating levels of active glucocorticoid cortisol contribute to various disorders such as diabetes mellitus, obesity, dyslipidemia and high blood pressure."
      },
      {
        "bel_statement": "a(CHEBI:17650) increases path(MESH:D009765)",
        "evidence": "Literature reports indicated that high circulating levels of active glucocorticoid cortisol contribute to various disorders such as diabetes mellitus, obesity, dyslipidemia and high blood pressure."
      },
      {
        "bel_statement": "a(CHEBI:17650) increases path(MESH:D008052)",
        "evidence": "Literature reports indicated that high circulating levels of active glucocorticoid cortisol contribute to various disorders such as diabetes mellitus, obesity, dyslipidemia and high blood pressure."
      },
      {
        "bel_statement": "a(CHEBI:17650) increases path(MESH:D006973)",
        "evidence": "Literature reports indicated that high circulating levels of active glucocorticoid cortisol contribute to various disorders such as diabetes mellitus, obesity, dyslipidemia and high blood pressure."
      },
      {
        "bel_statement": "a(MESH:D042842) increases path(DOID:14221)",
        "evidence": "whereas studies also suggested that the over expression of 11beta-HSD made animals prone to metabolic syndrome."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D042842",
        "entry_name": "11-beta-Hydroxysteroid Dehydrogenases"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:16962",
        "entry_name": "cortisone"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17650",
        "entry_name": "cortisol"
      },
      {
        "db": "MESH",
        "id": "D008091",
        "entry_name": "Literature"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24261",
        "entry_name": "glucocorticoid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17650",
        "entry_name": "cortisol"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "MESH",
        "id": "D008052",
        "entry_name": "Lipid Metabolism, Inborn Errors"
      },
      {
        "db": "MESH",
        "id": "D006973",
        "entry_name": "Hypertension"
      },
      {
        "db": "MESH",
        "id": "D008822",
        "entry_name": "Mice, Transgenic"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "1663",
        "entry_name": "CD36"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "DOID",
        "id": "DOID:14221",
        "entry_name": "abdominal obesity-metabolic syndrome 1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      }
    ]
  },
  {
    "Index": "27",
    "Results": [
      {
        "bel_statement": "a(CHEBI:28300) increases a(MESH:C027618)",
        "evidence": "Glutamine Fructose-6-Phosphate Amido Transferase"
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:28300",
        "entry_name": "glutamine"
      },
      {
        "db": "MESH",
        "id": "C027618",
        "entry_name": "fructose-6-phosphate"
      },
      {
        "db": "MESH",
        "id": "D014166",
        "entry_name": "Transferases"
      }
    ]
  },
  {
    "Index": "28",
    "Results": [
      {
        "bel_statement": "a(CHEBI:17234) increases bp(GO:0008152)",
        "evidence": "As reported earlier, most glucose entering the cell undergo glycolytic metabolism and a very small percentage enter the hexosamine pathway."
      },
      {
        "bel_statement": "bp(GO:0009058) increases EFO:0002614",
        "evidence": "Biosynthesis of hexosamine is well known for its contribution to insulin resistance and activation of growth factor synthesis."
      },
      {
        "bel_statement": "p(HGNC:GFPT1) hasActivity ma(MESH:D005945)",
        "evidence": "Enzyme Glutamine fructose-6-phosphate aminotransferase (GFAT) has a central role in the hexosamine biosynthetic pathway, as it is involved in catalysis of the first and rate limiting steps for hexosamine formation."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "GO",
        "id": "GO:0008152",
        "entry_name": "metabolic process"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24586",
        "entry_name": "hexosamine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      },
      {
        "db": "GO",
        "id": "GO:0009058",
        "entry_name": "biosynthetic process"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24586",
        "entry_name": "hexosamine"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "GO",
        "id": "GO:0009058",
        "entry_name": "biosynthetic process"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "MESH",
        "id": "D005945",
        "entry_name": "Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)"
      },
      {
        "db": "HGNC",
        "id": "4241",
        "entry_name": "GFPT1"
      },
      {
        "db": "HP",
        "id": "HP:0030645",
        "entry_name": "Central"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24586",
        "entry_name": "hexosamine"
      },
      {
        "db": "MESH",
        "id": "D053898",
        "entry_name": "Biosynthetic Pathways"
      },
      {
        "db": "MESH",
        "id": "D002384",
        "entry_name": "Catalysis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24586",
        "entry_name": "hexosamine"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      }
    ]
  },
  {
    "Index": "29",
    "Results": [
      {
        "bel_statement": "a(CHEBI:18186) increases a(FPLX:Phosphatase)",
        "evidence": "Protein Tyrosine Phosphatase 1B"
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:18186",
        "entry_name": "tyrosine"
      },
      {
        "db": "FPLX",
        "id": "Phosphatase",
        "entry_name": "Phosphatase"
      }
    ]
  },
  {
    "Index": "30",
    "Results": [
      {
        "bel_statement": "p(HGNC:PTPN1) decreases p(HGNC:INSR)",
        "evidence": "PTP1B dephosphorylates phosphor-tyrosine residues of insulin receptor kinase activation segments leading to negative regulation of insulin signaling."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) decreases bp(GO:0007165)",
        "evidence": "PTP1B dephosphorylates phosphor-tyrosine residues of insulin receptor kinase activation segments leading to negative regulation of insulin signaling."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) decreases bp(GO:0023052)",
        "evidence": "PTP1B is also a negative regulator for leptin signaling."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) increases path(MESH:D009765)",
        "evidence": "The evidence further suggests a relationship between PTP1B, insulin sensitivity, obesity and T2DM."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) increases bp(GO:0044342)",
        "evidence": "PTP1B also plays an important part in pancreatic beta-cell proliferation."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) increases bp(GO:0030073)",
        "evidence": "Fernandez-Ruiz et al. found that that PTP1B knockout mice have a higher proliferation of beta-cells and elevated glucose-induced insulin secretion."
      },
      {
        "bel_statement": "p(HGNC:PTPN1) increases path(MESH:D003920)",
        "evidence": "These studies are strongly suggestive of the role of PTP1B in diabetes, and thus interest for PTP1B inhibitors, resulting in the search for and development of several inhibitors of this protein."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:18186",
        "entry_name": "tyrosine"
      },
      {
        "db": "FPLX",
        "id": "Phosphatase",
        "entry_name": "Phosphatase"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18186",
        "entry_name": "tyrosine"
      },
      {
        "db": "FPLX",
        "id": "Phosphatase",
        "entry_name": "Phosphatase"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "HGNC",
        "id": "9670",
        "entry_name": "PTPRF"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0007165",
        "entry_name": "signal transduction"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18186",
        "entry_name": "tyrosine"
      },
      {
        "db": "HGNC",
        "id": "9657",
        "entry_name": "PTPN5"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0007165",
        "entry_name": "signal transduction"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "HGNC",
        "id": "6091",
        "entry_name": "INSR"
      },
      {
        "db": "MESH",
        "id": "D010770",
        "entry_name": "Phosphotransferases"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "HGNC",
        "id": "6553",
        "entry_name": "LEP"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "HGNC",
        "id": "6553",
        "entry_name": "LEP"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24621",
        "entry_name": "hormone"
      },
      {
        "db": "GO",
        "id": "GO:0042592",
        "entry_name": "homeostatic process"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "HGNC",
        "id": "6553",
        "entry_name": "LEP"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "GO",
        "id": "GO:0044342",
        "entry_name": "type B pancreatic cell proliferation"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28984",
        "entry_name": "aluminium atom"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "MESH",
        "id": "D018345",
        "entry_name": "Mice, Knockout"
      },
      {
        "db": "GO",
        "id": "GO:0008283",
        "entry_name": "cell population proliferation"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "HGNC",
        "id": "9642",
        "entry_name": "PTPN1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      }
    ]
  },
  {
    "Index": "31",
    "Results": [
      {
        "bel_statement": "g(HGNC:23093) decreases r(HGNC:23093)",
        "evidence": "These diabetes-associated haplotypes caused a decrease in SLC16A11 expression in the liver and disrupted interaction with basigin, which reduced the cell surface localization of SLC16A11."
      },
      {
        "bel_statement": "g(HGNC:23093) decreases complex(p(HGNC:23093), p(HGNC:1116))",
        "evidence": "These diabetes-associated haplotypes caused a decrease in SLC16A11 expression in the liver and disrupted interaction with basigin, which reduced the cell surface localization of SLC16A11."
      },
      {
        "bel_statement": "g(HGNC:23093) decreases surf(p(HGNC:23093))",
        "evidence": "These diabetes-associated haplotypes caused a decrease in SLC16A11 expression in the liver and disrupted interaction with basigin, which reduced the cell surface localization of SLC16A11."
      },
      {
        "bel_statement": "deg(p(HGNC:23093)) increases bp(GO:0006629)",
        "evidence": "SLC16A11 knockdown in primary human hepatocytes leads to modulation of fatty acid and lipid metabolism."
      },
      {
        "bel_statement": "bp(GO:0006629) increases a(CHEBI:17855)",
        "evidence": "This modulation increases intracellular acylcarnitine, diacylglycerol and triacylglycerol levels which results in increased triglycerides in blood circulation and an accumulation in liver tissue."
      },
      {
        "bel_statement": "a(CHEBI:17855) increases path(EFO:0002614)",
        "evidence": "The increased levels of triglycerides are implicated in insulin resistance, so variants of SLC16A11 may increase the risk of diabetes by regulating lipid metabolism."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "C033762",
        "entry_name": "S-Lim"
      },
      {
        "db": "MESH",
        "id": "D000088744",
        "entry_name": "Genomic Medicine"
      },
      {
        "db": "MESH",
        "id": "D000569",
        "entry_name": "Americas"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D056426",
        "entry_name": "Genetic Loci"
      },
      {
        "db": "MESH",
        "id": "D006239",
        "entry_name": "Haplotypes"
      },
      {
        "db": "HGNC",
        "id": "23093",
        "entry_name": "SLC16A11"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "HGNC",
        "id": "1116",
        "entry_name": "BSG"
      },
      {
        "db": "HGNC",
        "id": "23093",
        "entry_name": "SLC16A11"
      },
      {
        "db": "HGNC",
        "id": "23093",
        "entry_name": "SLC16A11"
      },
      {
        "db": "MESH",
        "id": "D006801",
        "entry_name": "Humans"
      },
      {
        "db": "MESH",
        "id": "D022781",
        "entry_name": "Hepatocytes"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35366",
        "entry_name": "fatty acid"
      },
      {
        "db": "GO",
        "id": "GO:0006629",
        "entry_name": "lipid metabolic process"
      },
      {
        "db": "GO",
        "id": "GO:0005622",
        "entry_name": "intracellular anatomical structure"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15414",
        "entry_name": "S-adenosyl-L-methionine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18035",
        "entry_name": "diglyceride"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17855",
        "entry_name": "triglyceride"
      },
      {
        "db": "MESH",
        "id": "D015228",
        "entry_name": "Hypertriglyceridemia"
      },
      {
        "db": "GO",
        "id": "GO:0008015",
        "entry_name": "blood circulation"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17855",
        "entry_name": "triglyceride"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "HGNC",
        "id": "23093",
        "entry_name": "SLC16A11"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "GO",
        "id": "GO:0006629",
        "entry_name": "lipid metabolic process"
      },
      {
        "db": "GO",
        "id": "GO:0006810",
        "entry_name": "transport"
      },
      {
        "db": "MESH",
        "id": "D000339",
        "entry_name": "Affect"
      }
    ]
  },
  {
    "Index": "32",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D009396",
        "entry_name": "Wilms Tumor"
      }
    ]
  },
  {
    "Index": "33",
    "Results": [
      {
        "bel_statement": "p(HGNC:CCN3) positiveCorrelation p(HGNC:CRP)",
        "evidence": "The average plasma levels of CCN3 have a strong correlation with hs-CRP, BMI, and fat mass, and are elevated significantly in obese patients with hyperlipidemia."
      },
      {
        "bel_statement": "p(HGNC:CCN3) positiveCorrelation path(DOID:9970)",
        "evidence": "The average plasma levels of CCN3 have a strong correlation with hs-CRP, BMI, and fat mass, and are elevated significantly in obese patients with hyperlipidemia."
      },
      {
        "bel_statement": "p(HGNC:CCN3) increases path(MESH:D013812)",
        "evidence": "These data suggest CCN3 may be involved in obesity-associated insulin-resistance and can serve as an important target for a T2DM therapeutic."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "MESH",
        "id": "D009396",
        "entry_name": "Wilms Tumor"
      },
      {
        "db": "HGNC",
        "id": "11219",
        "entry_name": "SPARC"
      },
      {
        "db": "MESH",
        "id": "D006801",
        "entry_name": "Humans"
      },
      {
        "db": "MESH",
        "id": "D014024",
        "entry_name": "Tissues"
      },
      {
        "db": "MESH",
        "id": "D009141",
        "entry_name": "Musculoskeletal System"
      },
      {
        "db": "MESH",
        "id": "D007668",
        "entry_name": "Kidney"
      },
      {
        "db": "MESH",
        "id": "D002555",
        "entry_name": "Cerebrospinal Fluid"
      },
      {
        "db": "MESH",
        "id": "D010949",
        "entry_name": "Plasma"
      },
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "HGNC",
        "id": "2367",
        "entry_name": "CRP"
      },
      {
        "db": "MESH",
        "id": "D015992",
        "entry_name": "Body Mass Index"
      },
      {
        "db": "HGNC",
        "id": "1663",
        "entry_name": "CD36"
      },
      {
        "db": "HGNC",
        "id": "3603",
        "entry_name": "FBN1"
      },
      {
        "db": "DOID",
        "id": "DOID:9970",
        "entry_name": "obesity"
      },
      {
        "db": "MESH",
        "id": "D006949",
        "entry_name": "Hyperlipidemias"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28984",
        "entry_name": "aluminium atom"
      },
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "HGNC",
        "id": "7094",
        "entry_name": "MICE"
      },
      {
        "db": "MESH",
        "id": "D059305",
        "entry_name": "Diet, High-Fat"
      },
      {
        "db": "MESH",
        "id": "D001835",
        "entry_name": "Body Weight"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:30145",
        "entry_name": "lithium atom"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28984",
        "entry_name": "aluminium atom"
      },
      {
        "db": "MESH",
        "id": "D044967",
        "entry_name": "Serum"
      },
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "HP",
        "id": "HP:0032322",
        "entry_name": "Healthy"
      },
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "HGNC",
        "id": "7885",
        "entry_name": "CCN3"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      }
    ]
  },
  {
    "Index": "34",
    "Results": [
      {
        "bel_statement": "p(HGNC:FOXO1) increases bp(GO:0006915)",
        "evidence": "Fox01 in the pancreas are responsible for beta-cell dysfunction by inducing stress and apoptosis."
      },
      {
        "bel_statement": "p(HGNC:FOXO1, pmod(Ph)) directlyIncreases p(HGNC:FOXO1, pmod(Ub))",
        "evidence": "Phosphorylation of FoxO1 is the main mechanism by which it comes out of the nucleus to get degraded by ubiquitination."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) directlyIncreases p(HGNC:FOXO1, pmod(Ph))",
        "evidence": "PGC1-alpha induction during fasting activates the series of gluconeogenesis genes and later directly binds to FoxO1 to phosphorylate and ultimately degrade it out of the nucleus."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D005546",
        "entry_name": "Forehead"
      },
      {
        "db": "MESH",
        "id": "D014157",
        "entry_name": "Transcription Factors"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "MESH",
        "id": "D017667",
        "entry_name": "Adipocytes"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D059305",
        "entry_name": "Diet, High-Fat"
      },
      {
        "db": "MESH",
        "id": "D010179",
        "entry_name": "Pancreas"
      },
      {
        "db": "HP",
        "id": "HP:0006279",
        "entry_name": "Beta-cell dysfunction"
      },
      {
        "db": "GO",
        "id": "GO:0006915",
        "entry_name": "apoptotic process"
      },
      {
        "db": "MESH",
        "id": "D000107",
        "entry_name": "Acetylation"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "GO",
        "id": "GO:0005634",
        "entry_name": "nucleus"
      },
      {
        "db": "HGNC",
        "id": "25559",
        "entry_name": "RESF1"
      },
      {
        "db": "MESH",
        "id": "D054875",
        "entry_name": "Ubiquitination"
      },
      {
        "db": "MESH",
        "id": "D000107",
        "entry_name": "Acetylation"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:141213",
        "entry_name": "isoxaflutole"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "HGNC",
        "id": "10261",
        "entry_name": "ROS1"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "MESH",
        "id": "D005215",
        "entry_name": "Fasting"
      },
      {
        "db": "GO",
        "id": "GO:0006094",
        "entry_name": "gluconeogenesis"
      },
      {
        "db": "HGNC",
        "id": "3819",
        "entry_name": "FOXO1"
      },
      {
        "db": "GO",
        "id": "GO:0005634",
        "entry_name": "nucleus"
      }
    ]
  },
  {
    "Index": "35",
    "Results": [
      {
        "bel_statement": "a(CHEBI:15904) increases p(HGNC:4501)",
        "evidence": "FFAs of these varying chain lengths are known to activate transmembrane receptors such as FFA1, FFA2, and FFA3. For example, FFA1 are expressed to a large extent on the pancreatic beta-cells and are activated by LCFAs."
      },
      {
        "bel_statement": "a(CHEBI:26666) increases p(HGNC:4501)",
        "evidence": "FFA2 and FFA3 are akin to FFA1 receptors and get activated by SCFAs but their role in insulin is complex."
      },
      {
        "bel_statement": "p(HGNC:4501) decreases bp(GO:0030073)",
        "evidence": "These receptors are shown to inhibit insulin secretion by coupling to Gi-type G proteins."
      },
      {
        "bel_statement": "a(CHEBI:48706) decreases bp(GO:0030073)",
        "evidence": "This study demonstrated that FFA2/FFA3 antagonists may prove beneficial in T2DM."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D005230",
        "entry_name": "Fatty Acids, Nonesterified"
      },
      {
        "db": "HGNC",
        "id": "16",
        "entry_name": "SERPINA3"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:62488",
        "entry_name": "signalling molecule"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26666",
        "entry_name": "short-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26666",
        "entry_name": "short-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:59554",
        "entry_name": "medium-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:59554",
        "entry_name": "medium-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15904",
        "entry_name": "long-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15904",
        "entry_name": "long-chain fatty acid"
      },
      {
        "db": "GO",
        "id": "GO:0016020",
        "entry_name": "membrane"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "HGNC",
        "id": "6511",
        "entry_name": "LARGE1"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15904",
        "entry_name": "long-chain fatty acid"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52214",
        "entry_name": "ligand"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "HGNC",
        "id": "25559",
        "entry_name": "RESF1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26666",
        "entry_name": "short-chain fatty acid"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D009504",
        "entry_name": "Neutrophils"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "EFO",
        "id": "0002829",
        "entry_name": "MIN6"
      },
      {
        "db": "MESH",
        "id": "D051379",
        "entry_name": "Mice"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D015994",
        "entry_name": "Incidence"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26666",
        "entry_name": "short-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52214",
        "entry_name": "ligand"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D001419",
        "entry_name": "Bacteria"
      },
      {
        "db": "GO",
        "id": "GO:0006113",
        "entry_name": "fermentation"
      },
      {
        "db": "MESH",
        "id": "D004043",
        "entry_name": "Dietary Fiber"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28984",
        "entry_name": "aluminium atom"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D006801",
        "entry_name": "Humans"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "FPLX",
        "id": "G_protein",
        "entry_name": "G_protein"
      },
      {
        "db": "EFO",
        "id": "0004014",
        "entry_name": "deletion"
      },
      {
        "db": "HGNC",
        "id": "4501",
        "entry_name": "FFAR2"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "EFO",
        "id": "0004014",
        "entry_name": "deletion"
      },
      {
        "db": "MESH",
        "id": "D000339",
        "entry_name": "Affect"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48706",
        "entry_name": "antagonist"
      }
    ]
  },
  {
    "Index": "36",
    "Results": [],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:64007",
        "entry_name": "EET"
      }
    ]
  },
  {
    "Index": "37",
    "Results": [
      {
        "bel_statement": "a(CHEBI:15843) increases a(CHEBI:64007)",
        "evidence": "Epoxyeicosatrienoic acids (EETs) are produced from arachidonic acid by cytochrome p450 enzymes (monoxygenase/epoxygenase) in vascular endothelium responses to various stimuli, such as the agonists acetylcholine (ACH) or bradykinin, or by shear stress which activates phospholipase A2 to release arachidonic acid."
      },
      {
        "bel_statement": "a(CHEBI:15843) increases a(CHEBI:34306)",
        "evidence": "The cytochrome p450 enzyme is responsible for the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) and EETs."
      },
      {
        "bel_statement": "a(CHEBI:64007) decreases act(p(HGNC:3402))",
        "evidence": "The literature shows that EETs demonstrate anti-inflammatory, vasodilatory, and anti-apoptotic actions, inhibited sEH significantly, and elevated EETs' cellular and circulation levels."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:64007",
        "entry_name": "EET"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15843",
        "entry_name": "arachidonic acid"
      },
      {
        "db": "FPLX",
        "id": "CYP",
        "entry_name": "CYP"
      },
      {
        "db": "MESH",
        "id": "D004730",
        "entry_name": "Endothelium, Vascular"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15355",
        "entry_name": "acetylcholine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15355",
        "entry_name": "acetylcholine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:3165",
        "entry_name": "bradykinin"
      },
      {
        "db": "FPLX",
        "id": "PLA2",
        "entry_name": "PLA2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15843",
        "entry_name": "arachidonic acid"
      },
      {
        "db": "FPLX",
        "id": "CYP",
        "entry_name": "CYP"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34306",
        "entry_name": "20-HETE"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34306",
        "entry_name": "20-HETE"
      },
      {
        "db": "HGNC",
        "id": "3402",
        "entry_name": "EPHX2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26523",
        "entry_name": "reactive oxygen species"
      },
      {
        "db": "HGNC",
        "id": "10261",
        "entry_name": "ROS1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:37527",
        "entry_name": "acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:37739",
        "entry_name": "glycerophospholipid"
      },
      {
        "db": "MESH",
        "id": "D008091",
        "entry_name": "Literature"
      },
      {
        "db": "HGNC",
        "id": "3402",
        "entry_name": "EPHX2"
      }
    ]
  },
  {
    "Index": "38",
    "Results": [
      {
        "bel_statement": "a(CHEBI:64007) decreases a(MESH:D050151)",
        "evidence": "The administration of EET or inhibitors of sEH to obese mice is associated with a decrease in visceral subcutaneous fat and an increase in insulin sensitivity."
      },
      {
        "bel_statement": "a(CHEBI:64007) increases a(HGNC:6081)",
        "evidence": "The administration of EET or inhibitors of sEH to obese mice is associated with a decrease in visceral subcutaneous fat and an increase in insulin sensitivity."
      },
      {
        "bel_statement": "a(CHEBI:64007) increases bp(GO:0019395)",
        "evidence": "The CYP2J2-mediated increase in EET increases fatty acid oxidation and adiposity."
      },
      {
        "bel_statement": "a(CHEBI:64007) increases a(MESH:D050154)",
        "evidence": "The CYP2J2-mediated increase in EET increases fatty acid oxidation and adiposity."
      },
      {
        "bel_statement": "bp(GO:0042311) decreases bp(GO:0006954)",
        "evidence": "Although EETs have a naturally robust action, including vasodilatation and restraint of the inflammatory response, in adiposity, their effect on mitochondrial work and proliferator-actuated receptor gamma coactivator-1alpha (PGC-1alpha) corresponding to adipogenesis is still unclear."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:64007",
        "entry_name": "EET"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "HGNC",
        "id": "3402",
        "entry_name": "EPHX2"
      },
      {
        "db": "MESH",
        "id": "D008820",
        "entry_name": "Mice, Obese"
      },
      {
        "db": "MESH",
        "id": "D050151",
        "entry_name": "Subcutaneous Fat"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:64007",
        "entry_name": "EET"
      },
      {
        "db": "GO",
        "id": "GO:0019395",
        "entry_name": "fatty acid oxidation"
      },
      {
        "db": "MESH",
        "id": "D050154",
        "entry_name": "Adiposity"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "GO",
        "id": "GO:0042311",
        "entry_name": "vasodilation"
      },
      {
        "db": "GO",
        "id": "GO:0006954",
        "entry_name": "inflammatory response"
      },
      {
        "db": "MESH",
        "id": "D050154",
        "entry_name": "Adiposity"
      },
      {
        "db": "MESH",
        "id": "D014937",
        "entry_name": "Work"
      },
      {
        "db": "GO",
        "id": "GO:0038023",
        "entry_name": "signaling receptor activity"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:30212",
        "entry_name": "photon"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "MESH",
        "id": "D050156",
        "entry_name": "Adipogenesis"
      }
    ]
  },
  {
    "Index": "39",
    "Results": [
      {
        "bel_statement": "p(HGNC:PPARGC1A) increases act(p(HGNC:PPARG))",
        "evidence": "Peroxisome Proliferator-Activated Receptor Gamma Co-Activator Alpha (PGC-1alpha)"
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "9236",
        "entry_name": "PPARG"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      }
    ]
  },
  {
    "Index": "40",
    "Results": [
      {
        "bel_statement": "p(HGNC:PPARGC1A) regulates bp(GO:0097009)",
        "evidence": "PGC-1alpha maintains energy homeostasis and regulates the expression of insulin signaling, mitochondrial biogenesis, dynamics, and antioxidant genes, including uncoupling proteins, and thus prevents mitochondrial dysfunction and metabolic disorders related to adipocyte malfunction."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) regulates p(HGNC:INS)",
        "evidence": "PGC-1alpha maintains energy homeostasis and regulates the expression of insulin signaling, mitochondrial biogenesis, dynamics, and antioxidant genes, including uncoupling proteins, and thus prevents mitochondrial dysfunction and metabolic disorders related to adipocyte malfunction."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) regulates a(CHEBI:CHEBI:22586)",
        "evidence": "PGC-1alpha maintains energy homeostasis and regulates the expression of insulin signaling, mitochondrial biogenesis, dynamics, and antioxidant genes, including uncoupling proteins, and thus prevents mitochondrial dysfunction and metabolic disorders related to adipocyte malfunction."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) decreases path(MESH:D008659)",
        "evidence": "PGC-1alpha maintains energy homeostasis and regulates the expression of insulin signaling, mitochondrial biogenesis, dynamics, and antioxidant genes, including uncoupling proteins, and thus prevents mitochondrial dysfunction and metabolic disorders related to adipocyte malfunction."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) decreases bp(GO:0006954)",
        "evidence": "Dysregulation of PGC-1alpha alters homeostasis in cells and exacerbates the inflammatory response, which is commonly accompanied by metabolic disturbances."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) decreases a(MESH:D011312)",
        "evidence": "During adipocyte dysfunction, low degrees of PGC-1alpha downregulate mitochondrial quality articulation, instigate irritation and oxidative pressure, and advance atomic factor kappa-B actuation."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "MESH",
        "id": "D006801",
        "entry_name": "Humans"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "GO",
        "id": "GO:0097009",
        "entry_name": "energy homeostasis"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:22586",
        "entry_name": "antioxidant"
      },
      {
        "db": "MESH",
        "id": "D000071245",
        "entry_name": "Mitochondrial Uncoupling Proteins"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "MESH",
        "id": "D017667",
        "entry_name": "Adipocytes"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "GO",
        "id": "GO:0042592",
        "entry_name": "homeostatic process"
      },
      {
        "db": "GO",
        "id": "GO:0006954",
        "entry_name": "inflammatory response"
      },
      {
        "db": "MESH",
        "id": "D017667",
        "entry_name": "Adipocytes"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "MESH",
        "id": "D011312",
        "entry_name": "Pressure"
      }
    ]
  },
  {
    "Index": "41",
    "Results": [
      {
        "bel_statement": "p(HGNC:PPARGC1A) increases a(MESH:Liver)",
        "evidence": "PGC-1alpha quality treatment facilitated improved fat tissue work and had a positive and beneficial effect on distal organs like the liver."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) increases bp(GO:\"insulin processing\")",
        "evidence": "Focusing on PGC-1alpha quality treatment is an alluring remedial methodology for improving insulin affectability, insulin processing, metabolic movement and vascular capacity in metabolic disorders."
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) increases path(MESH:\"Metabolic Diseases\")",
        "evidence": "Focusing on PGC-1alpha quality treatment is an alluring remedial methodology for improving insulin affectability, insulin processing, metabolic movement and vascular capacity in metabolic disorders."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "HGNC",
        "id": "1663",
        "entry_name": "CD36"
      },
      {
        "db": "MESH",
        "id": "D014937",
        "entry_name": "Work"
      },
      {
        "db": "EFO",
        "id": "0001655",
        "entry_name": "distal"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0030070",
        "entry_name": "insulin processing"
      },
      {
        "db": "MESH",
        "id": "D009068",
        "entry_name": "Movement"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      }
    ]
  },
  {
    "Index": "42",
    "Results": [],
    "annotations": [
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      }
    ]
  },
  {
    "Index": "43",
    "Results": [
      {
        "bel_statement": "p(FPLX:PPAR) increases bp(MESH:Adipogenesis)",
        "evidence": "Originally, it was considered the positive regulator of adipogenesis with higher expression in adipose tissues."
      },
      {
        "bel_statement": "p(FPLX:PPAR) increases p(HGNC:ADIPOQ)",
        "evidence": "PPAR is well known for both promoting and secreting adiponectin which is considered an important insulin sensitizing hormone."
      },
      {
        "bel_statement": "p(FPLX:PPAR) increases a(CHEBI:hormone)",
        "evidence": "PPAR is well known for both promoting and secreting adiponectin which is considered an important insulin sensitizing hormone."
      },
      {
        "bel_statement": "p(FPLX:PPAR) increases p(HGNC:INS)",
        "evidence": "PPAR is well known for both promoting and secreting adiponectin which is considered an important insulin sensitizing hormone."
      },
      {
        "bel_statement": "p(FPLX:PPAR) increases path(DOID:14221)",
        "evidence": "Sirtuins-mediated changes in PPAR also were beneficial in metabolic syndrome."
      }
    ],
    "annotations": [
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "MESH",
        "id": "D050156",
        "entry_name": "Adipogenesis"
      },
      {
        "db": "MESH",
        "id": "D000273",
        "entry_name": "Adipose Tissue"
      },
      {
        "db": "MESH",
        "id": "D014024",
        "entry_name": "Tissues"
      },
      {
        "db": "EFO",
        "id": "0004014",
        "entry_name": "deletion"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "MESH",
        "id": "D000273",
        "entry_name": "Adipose Tissue"
      },
      {
        "db": "MESH",
        "id": "D009132",
        "entry_name": "Muscles"
      },
      {
        "db": "MESH",
        "id": "D008264",
        "entry_name": "Macrophages"
      },
      {
        "db": "MESH",
        "id": "D001921",
        "entry_name": "Brain"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "HGNC",
        "id": "13633",
        "entry_name": "ADIPOQ"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24621",
        "entry_name": "hormone"
      },
      {
        "db": "MESH",
        "id": "D014157",
        "entry_name": "Transcription Factors"
      },
      {
        "db": "MESH",
        "id": "D032882",
        "entry_name": "Comprehension"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D006333",
        "entry_name": "Heart Failure"
      },
      {
        "db": "MESH",
        "id": "D015430",
        "entry_name": "Weight Gain"
      },
      {
        "db": "MESH",
        "id": "D001749",
        "entry_name": "Urinary Bladder Neoplasms"
      },
      {
        "db": "MESH",
        "id": "D010953",
        "entry_name": "Plasma Volume"
      },
      {
        "db": "MESH",
        "id": "D032882",
        "entry_name": "Comprehension"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      },
      {
        "db": "HGNC",
        "id": "17318",
        "entry_name": "RXFP2"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "GO",
        "id": "GO:0016925",
        "entry_name": "protein sumoylation"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "DOID",
        "id": "DOID:14221",
        "entry_name": "abdominal obesity-metabolic syndrome 1"
      }
    ]
  },
  {
    "Index": "44",
    "Results": [],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7978",
        "entry_name": "NR3C1"
      }
    ]
  },
  {
    "Index": "45",
    "Results": [
      {
        "bel_statement": "a(CHEBI:24261) increases a(MESH:D001786)",
        "evidence": "In general, glucocorticoids increase the blood glucose levels when required by the brain."
      },
      {
        "bel_statement": "act(p(HGNC:NR3C1)) increases a(EFO:0002614)",
        "evidence": "Chronic activation of these receptors is associated with metabolic dysfunction, including insulin resistance."
      },
      {
        "bel_statement": "act(p(HGNC:NR3C1)) increases bp(GO:0006508)",
        "evidence": "Chronic activation of these receptors inhibits protein synthesis and favors proteolysis."
      },
      {
        "bel_statement": "act(p(HGNC:NR3C1)) decreases bp(GO:0009058)",
        "evidence": "Chronic activation of these receptors inhibits protein synthesis and favors proteolysis."
      },
      {
        "bel_statement": "act(p(HGNC:NR3C1)) decreases bp(GO:0046323)",
        "evidence": "GR activation inhibits insulin stimulated glucose uptake by controlling many downstream targets."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7978",
        "entry_name": "NR3C1"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24261",
        "entry_name": "glucocorticoid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24261",
        "entry_name": "glucocorticoid"
      },
      {
        "db": "MESH",
        "id": "D001786",
        "entry_name": "Blood Glucose"
      },
      {
        "db": "MESH",
        "id": "D001921",
        "entry_name": "Brain"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:24261",
        "entry_name": "glucocorticoid"
      },
      {
        "db": "MESH",
        "id": "D020476",
        "entry_name": "Exhibition"
      },
      {
        "db": "MESH",
        "id": "D014157",
        "entry_name": "Transcription Factors"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "HGNC",
        "id": "8724",
        "entry_name": "PCK1"
      },
      {
        "db": "HGNC",
        "id": "4056",
        "entry_name": "G6PC1"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "GO",
        "id": "GO:0009058",
        "entry_name": "biosynthetic process"
      },
      {
        "db": "GO",
        "id": "GO:0006508",
        "entry_name": "proteolysis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:33709",
        "entry_name": "amino acid"
      },
      {
        "db": "EFO",
        "id": "0005061",
        "entry_name": "substrate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "HGNC",
        "id": "4623",
        "entry_name": "GSR"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0046323",
        "entry_name": "glucose import"
      },
      {
        "db": "EFO",
        "id": "0001461",
        "entry_name": "control"
      }
    ]
  },
  {
    "Index": "46",
    "Results": [],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      }
    ]
  },
  {
    "Index": "47",
    "Results": [
      {
        "bel_statement": "p(HGNC:7782) decreases a(FPLX:G6Pase)",
        "evidence": "In addition, one study involved induction of NRF2 in obese diabetic db/db mice, displaying a decreased blood glucose level by suppressing hepatic glucose 6 phosphatase via cAMP-CREB signaling."
      },
      {
        "bel_statement": "p(HGNC:7782) increases bp(MESH:D050156)",
        "evidence": "This suggests that NRF2 is a key player in adipogenesis or in other metabolic disorders."
      },
      {
        "bel_statement": "p(HGNC:7782) decreases bp(GO:0006915)",
        "evidence": "NRF2 knockdown enhances the palmitate-induced apoptosis in hepatocytes of obese patients."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "MESH",
        "id": "D019610",
        "entry_name": "Cytoprotection"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50906",
        "entry_name": "role"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D055808",
        "entry_name": "Drug Discovery"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D020641",
        "entry_name": "Polymorphism, Single Nucleotide"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "DOID",
        "id": "DOID:9970",
        "entry_name": "obesity"
      },
      {
        "db": "HGNC",
        "id": "7094",
        "entry_name": "MICE"
      },
      {
        "db": "MESH",
        "id": "D001786",
        "entry_name": "Blood Glucose"
      },
      {
        "db": "FPLX",
        "id": "G6Pase",
        "entry_name": "G6Pase"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "HGNC",
        "id": "6553",
        "entry_name": "LEP"
      },
      {
        "db": "HGNC",
        "id": "7094",
        "entry_name": "MICE"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "HGNC",
        "id": "1663",
        "entry_name": "CD36"
      },
      {
        "db": "HGNC",
        "id": "3603",
        "entry_name": "FBN1"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "MESH",
        "id": "D050156",
        "entry_name": "Adipogenesis"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "HP",
        "id": "HP:0011009",
        "entry_name": "Acute"
      },
      {
        "db": "EFO",
        "id": "0000428",
        "entry_name": "dose"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D011236",
        "entry_name": "Prediabetic State"
      },
      {
        "db": "MESH",
        "id": "D003930",
        "entry_name": "Diabetic Retinopathy"
      },
      {
        "db": "HGNC",
        "id": "7782",
        "entry_name": "NFE2L2"
      },
      {
        "db": "GO",
        "id": "GO:0006915",
        "entry_name": "apoptotic process"
      },
      {
        "db": "MESH",
        "id": "D022781",
        "entry_name": "Hepatocytes"
      },
      {
        "db": "DOID",
        "id": "DOID:9970",
        "entry_name": "obesity"
      }
    ]
  },
  {
    "Index": "48",
    "Results": [
      {
        "bel_statement": "p(HGNC:MME) directlyDecreases a(CHEBI:peptide hormone)",
        "evidence": "Neprilysin is a zinc-dependent metalloprotease that cleaves peptides (GLP-1 amide, GLP-1 amide from GLP-1 amide and GLP-1 amide) and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin."
      },
      {
        "bel_statement": "a(CHEBI:metabolite) increases a(CHEBI:antioxidant)",
        "evidence": "It has been found that direct administration of these metabolites has antioxidant, anti-apoptotic, and proliferative effects on pancreatic beta-cells by modulating energy homeostasis."
      },
      {
        "bel_statement": "a(CHEBI:metabolite) decreases bp(GO:apoptotic process)",
        "evidence": "It has been found that direct administration of these metabolites has antioxidant, anti-apoptotic, and proliferative effects on pancreatic beta-cells by modulating energy homeostasis."
      },
      {
        "bel_statement": "a(CHEBI:metabolite) increases bp(GO:cell population proliferation)",
        "evidence": "It has been found that direct administration of these metabolites has antioxidant, anti-apoptotic, and proliferative effects on pancreatic beta-cells by modulating energy homeostasis."
      },
      {
        "bel_statement": "a(CHEBI:metabolite) decreases bp(GO:apoptotic process)",
        "evidence": "It has been reported that these metabolites preserve mitochondrial function, inhibit membrane depolarization and caspase activation and hence, apoptosis of INS-1 beta-cells."
      },
      {
        "bel_statement": "a(CHEBI:metabolite) decreases path(MESH:Diabetes Mellitus)",
        "evidence": "The effect of these metabolites on diabetes is further demonstrated by the administration of GLP-1 amide, which increases beta-cell mass and proliferation by activation of the cAMP/PKA signaling cascade and phosphorylation of the Wnt/beta-catenin signaling pathway."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "7154",
        "entry_name": "MME"
      },
      {
        "db": "MESH",
        "id": "D045726",
        "entry_name": "Metalloproteases"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:16670",
        "entry_name": "peptide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25905",
        "entry_name": "peptide hormone"
      },
      {
        "db": "HGNC",
        "id": "4191",
        "entry_name": "GCG"
      },
      {
        "db": "MESH",
        "id": "D004745",
        "entry_name": "Enkephalins"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:80308",
        "entry_name": "substance P"
      },
      {
        "db": "HGNC",
        "id": "8038",
        "entry_name": "NTS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:7872",
        "entry_name": "oxytocin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:3165",
        "entry_name": "bradykinin"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "MESH",
        "id": "D010949",
        "entry_name": "Plasma"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25212",
        "entry_name": "metabolite"
      },
      {
        "db": "HGNC",
        "id": "4270",
        "entry_name": "GIP"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "HGNC",
        "id": "3009",
        "entry_name": "DPP4"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25212",
        "entry_name": "metabolite"
      },
      {
        "db": "HGNC",
        "id": "4191",
        "entry_name": "GCG"
      },
      {
        "db": "HGNC",
        "id": "4324",
        "entry_name": "GLP1R"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25212",
        "entry_name": "metabolite"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:22586",
        "entry_name": "antioxidant"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "GO",
        "id": "GO:0097009",
        "entry_name": "energy homeostasis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25212",
        "entry_name": "metabolite"
      },
      {
        "db": "FPLX",
        "id": "Caspase",
        "entry_name": "Caspase"
      },
      {
        "db": "GO",
        "id": "GO:0006915",
        "entry_name": "apoptotic process"
      },
      {
        "db": "EFO",
        "id": "0002529",
        "entry_name": "INS-1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25212",
        "entry_name": "metabolite"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:32988",
        "entry_name": "amide"
      },
      {
        "db": "HGNC",
        "id": "3603",
        "entry_name": "FBN1"
      },
      {
        "db": "GO",
        "id": "GO:0008283",
        "entry_name": "cell population proliferation"
      },
      {
        "db": "GO",
        "id": "GO:0023052",
        "entry_name": "signaling"
      },
      {
        "db": "GO",
        "id": "GO:0007165",
        "entry_name": "signal transduction"
      }
    ]
  },
  {
    "Index": "49",
    "Results": [
      {
        "bel_statement": "a(CHEBI:23888) decreases path(MESH:D003920)",
        "evidence": "Drugs Targeting Molecular Pathways Implicated in Diabetes and CVD"
      },
      {
        "bel_statement": "a(CHEBI:23888) decreases path(MESH:D002318)",
        "evidence": "Drugs Targeting Molecular Pathways Implicated in Diabetes and CVD"
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      }
    ]
  },
  {
    "Index": "50",
    "Results": [
      {
        "bel_statement": "p(HGNC:HSD11B1) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:HSD11B1) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:GPR119) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:GPR119) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:GPBAR1) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:GPBAR1) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:SIRT1) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:SIRT1) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:FFAR1) association path(MESH:D003920)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      },
      {
        "bel_statement": "p(HGNC:FFAR1) association path(MESH:D002318)",
        "evidence": "Such methodologies incorporate the focusing of 11-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), GPR119, TGR5, sirtuin 1 (SIRT1), the sodium-glucose co-carrier 2 (SGLT2), and GPR40, for every one of which the reasoning is briefly depicted below (Table 3)."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D012816",
        "entry_name": "Signs and Symptoms"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D019368",
        "entry_name": "Nature"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "EFO",
        "id": "0022481",
        "entry_name": "decreased risk"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "MESH",
        "id": "D042842",
        "entry_name": "11-beta-Hydroxysteroid Dehydrogenases"
      },
      {
        "db": "HGNC",
        "id": "5208",
        "entry_name": "HSD11B1"
      },
      {
        "db": "HGNC",
        "id": "19060",
        "entry_name": "GPR119"
      },
      {
        "db": "HGNC",
        "id": "19680",
        "entry_name": "GPBAR1"
      },
      {
        "db": "HGNC",
        "id": "14929",
        "entry_name": "SIRT1"
      },
      {
        "db": "HGNC",
        "id": "14929",
        "entry_name": "SIRT1"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "HGNC",
        "id": "4498",
        "entry_name": "FFAR1"
      },
      {
        "db": "EFO",
        "id": "0004350",
        "entry_name": "reasoning"
      },
      {
        "db": "MESH",
        "id": "D020501",
        "entry_name": "Tables"
      }
    ]
  },
  {
    "Index": "51",
    "Results": [
      {
        "bel_statement": "a(CHEBI:35222) increases path(MESH:D008659)",
        "evidence": "Taken together, these clinical findings give convincing evidence that various inhibitors, activators, agonists, and antagonists hold promise as new treatments for T2DM and related metabolic disorders."
      },
      {
        "bel_statement": "a(CHEBI:48705) increases path(MESH:D008659)",
        "evidence": "Taken together, these clinical findings give convincing evidence that various inhibitors, activators, agonists, and antagonists hold promise as new treatments for T2DM and related metabolic disorders."
      },
      {
        "bel_statement": "a(CHEBI:48706) increases path(MESH:D008659)",
        "evidence": "Taken together, these clinical findings give convincing evidence that various inhibitors, activators, agonists, and antagonists hold promise as new treatments for T2DM and related metabolic disorders."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D012816",
        "entry_name": "Signs and Symptoms"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48706",
        "entry_name": "antagonist"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:4471",
        "entry_name": "dextromethorphan hydrobromide"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      }
    ]
  },
  {
    "Index": "52",
    "Results": [
      {
        "bel_statement": "a(MESH:D004032) regulates a(MESH:D000069196)",
        "evidence": "Diabetes and the Gut Microbiota: Dietary Influence"
      },
      {
        "bel_statement": "a(MESH:D000069196) positiveCorrelation path(MESH:D003920)",
        "evidence": "Diabetes and the Gut Microbiota: Dietary Influence"
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      }
    ]
  },
  {
    "Index": "53",
    "Results": [
      {
        "bel_statement": "a(MESH:D004032) increases a(MESH:D000069196)",
        "evidence": "Diet is a key factor influencing the composition of the gut microbiome, indicating the potential for therapeutic dietary strategies to manipulate microbial diversity, composition, and stability."
      },
      {
        "bel_statement": "a(MESH:D000069196) increases a(GO:GO:0006805)",
        "evidence": "In addition, it was found that gut microbiota participates in drug metabolism by producing specific enzymes, such as reductase and hydrolytic enzymes, thus affecting the efficacy, toxicity, and bioavailability of drugs."
      },
      {
        "bel_statement": "a(CHEBI:33281) increases a(MESH:D064806)",
        "evidence": "Various antibiotics also alter the diversity and composition of gut microbiota which leads to dysbiosis, and it was found to be linked with progression of various neurodegenerative as well as metabolic disorders."
      },
      {
        "bel_statement": "a(MESH:D064806) increases path(MESH:D008659)",
        "evidence": "Various antibiotics also alter the diversity and composition of gut microbiota which leads to dysbiosis, and it was found to be linked with progression of various neurodegenerative as well as metabolic disorders."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D051379",
        "entry_name": "Mice"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "GO",
        "id": "GO:0006805",
        "entry_name": "xenobiotic metabolic process"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "HGNC",
        "id": "23316",
        "entry_name": "HSD17B6"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "EFO",
        "id": "0011061",
        "entry_name": "toxicity"
      },
      {
        "db": "MESH",
        "id": "D001682",
        "entry_name": "Biological Availability"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:33281",
        "entry_name": "antimicrobial agent"
      },
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D064806",
        "entry_name": "Dysbiosis"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      }
    ]
  },
  {
    "Index": "54",
    "Results": [
      {
        "bel_statement": "path(MESH:D064806) increases path(DOID:14221)",
        "evidence": "Gut microbiota dysbiosis has been found as a major culprit in initiation as well as progression of various metabolic syndromes including diabetes mellitus."
      },
      {
        "bel_statement": "path(MESH:D064806) increases path(MESH:D003920)",
        "evidence": "Gut microbiota dysbiosis has been found as a major culprit in initiation as well as progression of various metabolic syndromes including diabetes mellitus."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D000069196",
        "entry_name": "Gastrointestinal Microbiome"
      },
      {
        "db": "MESH",
        "id": "D064806",
        "entry_name": "Dysbiosis"
      },
      {
        "db": "DOID",
        "id": "DOID:14221",
        "entry_name": "abdominal obesity-metabolic syndrome 1"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "DOID",
        "id": "DOID:14221",
        "entry_name": "abdominal obesity-metabolic syndrome 1"
      }
    ]
  },
  {
    "Index": "55",
    "Results": [
      {
        "bel_statement": "a(CHEBI:28088) decreases a(CHEBI:17234)",
        "evidence": "Isoflavone (genistein) reduced fasting glucose and insulin, as well as HOMA-IR, fibrinogen, and homocysteine levels."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases p(HGNC:INS)",
        "evidence": "Isoflavone (genistein) reduced fasting glucose and insulin, as well as HOMA-IR, fibrinogen, and homocysteine levels."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases a(EFO:0004501)",
        "evidence": "Isoflavone (genistein) reduced fasting glucose and insulin, as well as HOMA-IR, fibrinogen, and homocysteine levels."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases a(FPLX:Fibrinogen)",
        "evidence": "Isoflavone (genistein) reduced fasting glucose and insulin, as well as HOMA-IR, fibrinogen, and homocysteine levels."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases a(EFO:0004578)",
        "evidence": "Isoflavone (genistein) reduced fasting glucose and insulin, as well as HOMA-IR, fibrinogen, and homocysteine levels."
      },
      {
        "bel_statement": "a(CHEBI:18220) decreases path(MESH:D003920)",
        "evidence": "Isoflavones have been shown to have anti-diabetic benefits due to their a-glucosidase inhibitory activity."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases path(MESH:D003920)",
        "evidence": "It is thought that genistein prevents diabetes by preserving insulin-positive beta-cells and altering the hepatic glucose metabolic enzyme profile."
      },
      {
        "bel_statement": "a(CHEBI:28088) decreases a(MESH:D015227)",
        "evidence": "Genistein may prevent glucose-induced lipid peroxidation, modify cell islet pancreatic function, and increase basal metabolic rate and energy metabolism."
      },
      {
        "bel_statement": "a(CHEBI:28088) increases a(MESH:D004734)",
        "evidence": "Genistein may prevent glucose-induced lipid peroxidation, modify cell islet pancreatic function, and increase basal metabolic rate and energy metabolism."
      },
      {
        "bel_statement": "a(CHEBI:28088) increases a(CHEBI:50114)",
        "evidence": "In vitro and in vivo studies have shown that genistein can serve as an estrogen agonist, resulting in the growth of estrogen-dependent human breast cancer tumors."
      },
      {
        "bel_statement": "a(CHEBI:28088) increases path(MESH:D001943)",
        "evidence": "In vitro and in vivo studies have shown that genistein can serve as an estrogen agonist, resulting in the growth of estrogen-dependent human breast cancer tumors."
      },
      {
        "bel_statement": "a(CHEBI:76989) increases path(MESH:D004714)",
        "evidence": "Long-term treatment with soy phytoestrogens has been linked to an increased risk of endometrial hyperplasia."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:18220",
        "entry_name": "isoflavone"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28088",
        "entry_name": "genistein"
      },
      {
        "db": "MESH",
        "id": "D005215",
        "entry_name": "Fasting"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "EFO",
        "id": "0004501",
        "entry_name": "HOMA-IR"
      },
      {
        "db": "FPLX",
        "id": "Fibrinogen",
        "entry_name": "Fibrinogen"
      },
      {
        "db": "EFO",
        "id": "0004578",
        "entry_name": "homocysteine measurement"
      },
      {
        "db": "HP",
        "id": "HP:0032322",
        "entry_name": "Healthy"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28088",
        "entry_name": "genistein"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:166892",
        "entry_name": "aglycone"
      },
      {
        "db": "EFO",
        "id": "0002721",
        "entry_name": "postmenopausal"
      },
      {
        "db": "MESH",
        "id": "D014930",
        "entry_name": "Women"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18220",
        "entry_name": "isoflavone"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28088",
        "entry_name": "genistein"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28088",
        "entry_name": "genistein"
      },
      {
        "db": "MESH",
        "id": "D015227",
        "entry_name": "Lipid Peroxidation"
      },
      {
        "db": "MESH",
        "id": "D004734",
        "entry_name": "Energy Metabolism"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:28088",
        "entry_name": "genistein"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50114",
        "entry_name": "estrogen"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "MESH",
        "id": "D006801",
        "entry_name": "Humans"
      },
      {
        "db": "MESH",
        "id": "D001943",
        "entry_name": "Breast Neoplasms"
      },
      {
        "db": "MESH",
        "id": "D009369",
        "entry_name": "Neoplasms"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:76989",
        "entry_name": "phytoestrogen"
      },
      {
        "db": "EFO",
        "id": "0005847",
        "entry_name": "increased risk"
      },
      {
        "db": "MESH",
        "id": "D004714",
        "entry_name": "Endometrial Hyperplasia"
      }
    ]
  },
  {
    "Index": "56",
    "Results": [
      {
        "bel_statement": "path(MESH:D003920) association path(MESH:D005234)",
        "evidence": "Crosstalk between Diabetes and Fatty Liver Disease-NASH and Prospective Therapeutic Drug Targets"
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D005234",
        "entry_name": "Fatty Liver"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      }
    ]
  },
  {
    "Index": "57",
    "Results": [
      {
        "bel_statement": "bp(GO:0006629) association path(DOID:0080547)",
        "evidence": "Altered glucose and lipid metabolism are key factors associated with the development of NASH."
      },
      {
        "bel_statement": "path(MESH:D008659) association path(DOID:0080547)",
        "evidence": "Studies have shown the close relationship between metabolic disease and NASH."
      },
      {
        "bel_statement": "path(DOID:0080547) increases a(HGNC:INS)",
        "evidence": "Although most of the patients with NASH are insulin resistant, they do not show hyperglycemia because of decreased ability of the liver to clear insulin."
      },
      {
        "bel_statement": "path(DOID:0080547) association path(MESH:D003920)",
        "evidence": "NASH patients only develop diabetes when pancreatic beta cells are unable to increase insulin secretion to match the insulin resistance."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "GO",
        "id": "GO:0006629",
        "entry_name": "lipid metabolic process"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HP",
        "id": "HP:0032322",
        "entry_name": "Healthy"
      },
      {
        "db": "MESH",
        "id": "D001835",
        "entry_name": "Body Weight"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D050417",
        "entry_name": "Insulin-Secreting Cells"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      }
    ]
  },
  {
    "Index": "58",
    "Results": [
      {
        "bel_statement": "p(HGNC:ZGLP1) increases a(EFO:0002614)",
        "evidence": "Glucagon-like-peptide-1 (GLP-1) receptors, which are used as second-line therapy for diabetes, have been used for amelioration of insulin resistance in NASH patients which ultimately improves the hepatic condition."
      },
      {
        "bel_statement": "a(CHEBI:6801) increases a(MESH:D003920)",
        "evidence": "Dipeptidyl peptidase (DPP)-4 inhibitors are another diabetic lowering class of agents that can be used for the treatment of NASH. Although these agents are not potent glucose-lowering agents due to their oral intake and low safety, these are used in combination with metformin in the management of diabetes."
      },
      {
        "bel_statement": "a(CHEBI:8228) increases path(DOID:0080547)",
        "evidence": "Pioglitazone, an anti-diabetic drug, has been shown to improve the condition in 60% of NASH patients."
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) increases bp(GO:0042593)",
        "evidence": "SGLT2 can be used for the treatment of NASH as it is helpful in glucose homeostasis."
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) decreases a(MESH:D005234)",
        "evidence": "It has been shown to reverse liver steatosis and hepatocytes necrosis."
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) decreases a(MESH:D000637)",
        "evidence": "These agents have been shown to decrease the plasma aminotransferases resulting in weight reduction which ultimately improves liver steatosis."
      },
      {
        "bel_statement": "p(HGNC:INS) increases a(MESH:D005234)",
        "evidence": "Insulin has been under research for the treatment of liver steatosis and improvement in NASH."
      }
    ],
    "annotations": [
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "MESH",
        "id": "D001835",
        "entry_name": "Body Weight"
      },
      {
        "db": "MESH",
        "id": "D012108",
        "entry_name": "Research Personnel"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "FPLX",
        "id": "Protease",
        "entry_name": "Protease"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34680",
        "entry_name": "dipentyl phthalate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35222",
        "entry_name": "inhibitor"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "MESH",
        "id": "D012449",
        "entry_name": "Safety"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:6801",
        "entry_name": "metformin"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:8228",
        "entry_name": "pioglitazone"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "MESH",
        "id": "D005234",
        "entry_name": "Fatty Liver"
      },
      {
        "db": "MESH",
        "id": "D022781",
        "entry_name": "Hepatocytes"
      },
      {
        "db": "GO",
        "id": "GO:0070265",
        "entry_name": null
      },
      {
        "db": "MESH",
        "id": "D010949",
        "entry_name": "Plasma"
      },
      {
        "db": "MESH",
        "id": "D000637",
        "entry_name": "Transaminases"
      },
      {
        "db": "MESH",
        "id": "D015431",
        "entry_name": "Weight Loss"
      },
      {
        "db": "MESH",
        "id": "D005234",
        "entry_name": "Fatty Liver"
      },
      {
        "db": "GO",
        "id": "GO:1901142",
        "entry_name": "insulin metabolic process"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D012106",
        "entry_name": "Research"
      },
      {
        "db": "MESH",
        "id": "D005234",
        "entry_name": "Fatty Liver"
      },
      {
        "db": "DOID",
        "id": "DOID:0080547",
        "entry_name": "metabolic dysfunction-associated steatohepatitis"
      }
    ]
  },
  {
    "Index": "59",
    "Results": [],
    "annotations": []
  },
  {
    "Index": "60",
    "Results": [
      {
        "bel_statement": "a(CHEBI:17234) increases a(MESH:D004231)",
        "evidence": "Osmotic diuresis is possible as glucose excreted in the urine also increases water and solute output, which can further lead to ketoacidosis or acidosis by hyperkaliemia and renal insufficiency."
      },
      {
        "bel_statement": "a(CHEBI:27881) increases act(p(HGNC:14929))",
        "evidence": "Currently, the search for new drug molecules that can activate sirtuins is of peak interest, and here resveratrol is considered the best characterized compound. However, it does not activate SIRT1 directly."
      },
      {
        "bel_statement": "a(CHEBI:183639) increases act(p(HGNC:14929))",
        "evidence": "Many similar molecular structures have been made of SRT1720 and SRT2104, which are active. Still, they need some substrate, and surprisingly they activate some fluorophore tags. They activate SIRT1 directly if endogenous sirtuin is similar to the fluorophore substrate (Figure 2)."
      },
      {
        "bel_statement": "a(MESH:C584666) increases act(p(HGNC:14929))",
        "evidence": "Many similar molecular structures have been made of SRT1720 and SRT2104, which are active. Still, they need some substrate, and surprisingly they activate some fluorophore tags. They activate SIRT1 directly if endogenous sirtuin is similar to the fluorophore substrate (Figure 2)."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D009017",
        "entry_name": "Morbidity"
      },
      {
        "db": "MESH",
        "id": "D009026",
        "entry_name": "Mortality"
      },
      {
        "db": "MESH",
        "id": "D009017",
        "entry_name": "Morbidity"
      },
      {
        "db": "HGNC",
        "id": "12703",
        "entry_name": "BEST1"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "EFO",
        "id": "0002571",
        "entry_name": "medical procedure"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "EFO",
        "id": "0002752",
        "entry_name": "aggressive"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "MESH",
        "id": "D012307",
        "entry_name": "Risk Factors"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:38960",
        "entry_name": "terbufos"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D016430",
        "entry_name": "Clinical Trial"
      },
      {
        "db": "MESH",
        "id": "D002181",
        "entry_name": "Candidiasis, Vulvovaginal"
      },
      {
        "db": "EFO",
        "id": "0000544",
        "entry_name": "infection"
      },
      {
        "db": "MESH",
        "id": "D005260",
        "entry_name": "Female"
      },
      {
        "db": "MESH",
        "id": "D004231",
        "entry_name": "Diuresis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "MESH",
        "id": "D014556",
        "entry_name": "Urine"
      },
      {
        "db": "MESH",
        "id": "D007662",
        "entry_name": "Ketosis"
      },
      {
        "db": "MESH",
        "id": "D000138",
        "entry_name": "Acidosis"
      },
      {
        "db": "MESH",
        "id": "D051437",
        "entry_name": "Renal Insufficiency"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25367",
        "entry_name": "molecule"
      },
      {
        "db": "MESH",
        "id": "D037761",
        "entry_name": "Sirtuins"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:27881",
        "entry_name": "resveratrol"
      },
      {
        "db": "HGNC",
        "id": "12703",
        "entry_name": "BEST1"
      },
      {
        "db": "HGNC",
        "id": "14929",
        "entry_name": "SIRT1"
      },
      {
        "db": "MESH",
        "id": "D015394",
        "entry_name": "Molecular Structure"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:183639",
        "entry_name": "SRT 1720"
      },
      {
        "db": "MESH",
        "id": "C584666",
        "entry_name": "SRT2104"
      },
      {
        "db": "EFO",
        "id": "0005061",
        "entry_name": "substrate"
      },
      {
        "db": "HGNC",
        "id": "14929",
        "entry_name": "SIRT1"
      },
      {
        "db": "MESH",
        "id": "D037761",
        "entry_name": "Sirtuins"
      },
      {
        "db": "EFO",
        "id": "0005061",
        "entry_name": "substrate"
      }
    ]
  },
  {
    "Index": "61",
    "Results": [
      {
        "bel_statement": "a(MESH:D057185) increases path(MESH:D009765)",
        "evidence": "Lamentably, sedentary lifestyles and uneven dietary preferences have contributed to the current obesity pandemic."
      },
      {
        "bel_statement": "a(MESH:D004032) increases path(MESH:D009765)",
        "evidence": "Lamentably, sedentary lifestyles and uneven dietary preferences have contributed to the current obesity pandemic."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "3242",
        "entry_name": "EHD1"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D000085002",
        "entry_name": "Glycemic Control"
      },
      {
        "db": "MESH",
        "id": "D032882",
        "entry_name": "Comprehension"
      },
      {
        "db": "MESH",
        "id": "D004194",
        "entry_name": "Disease"
      },
      {
        "db": "MESH",
        "id": "D010336",
        "entry_name": "Pathology"
      },
      {
        "db": "HGNC",
        "id": "17318",
        "entry_name": "RXFP2"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D057185",
        "entry_name": "Sedentary Behavior"
      },
      {
        "db": "MESH",
        "id": "D004032",
        "entry_name": "Diet"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "MESH",
        "id": "D058873",
        "entry_name": "Pandemics"
      },
      {
        "db": "MESH",
        "id": "D011236",
        "entry_name": "Prediabetic State"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "62",
    "Results": [
      {
        "bel_statement": "a(MESH:D006442) decreases path(MESH:D048909)",
        "evidence": "HbA1c-reducing agents are being evaluated in large clinical trials such as ACCORD, ADVANCE and VADT, in which improved control of HbA1c levels did result in reductions of serious microvascular diabetic complications."
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "6511",
        "entry_name": "LARGE1"
      },
      {
        "db": "MESH",
        "id": "D016430",
        "entry_name": "Clinical Trial"
      },
      {
        "db": "MESH",
        "id": "D006442",
        "entry_name": "Glycated Hemoglobin"
      },
      {
        "db": "MESH",
        "id": "D048909",
        "entry_name": "Diabetes Complications"
      },
      {
        "db": "EFO",
        "id": "0000544",
        "entry_name": "infection"
      },
      {
        "db": "MESH",
        "id": "D009026",
        "entry_name": "Mortality"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D019484",
        "entry_name": "Address"
      }
    ]
  },
  {
    "Index": "63",
    "Results": [
      {
        "bel_statement": "path(MESH:D003920) association path(MESH:D008107)",
        "evidence": "These studies include research focused on cardiovascular involvement and liver diseases, among many others."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D019368",
        "entry_name": "Nature"
      },
      {
        "db": "MESH",
        "id": "D011996",
        "entry_name": "Records"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D012106",
        "entry_name": "Research"
      },
      {
        "db": "MESH",
        "id": "D008107",
        "entry_name": "Liver Diseases"
      },
      {
        "db": "HGNC",
        "id": "6511",
        "entry_name": "LARGE1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:4471",
        "entry_name": "dextromethorphan hydrobromide"
      },
      {
        "db": "HGNC",
        "id": "17318",
        "entry_name": "RXFP2"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      }
    ]
  },
  {
    "Index": "64",
    "Results": [],
    "annotations": []
  },
  {
    "Index": "65",
    "Results": [],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      }
    ]
  },
  {
    "Index": "66",
    "Results": [
      {
        "bel_statement": "a(CHEBI:23888) increases a(MESH:D000085002)",
        "evidence": "Future drug and therapeutic developments must follow a holistic approach with special focus on the following points: (1) they should target mechanisms to achieve efficient glycemic control with a safe weight loss profile."
      },
      {
        "bel_statement": "a(CHEBI:23888) increases a(MESH:D015431)",
        "evidence": "Future drug and therapeutic developments must follow a holistic approach with special focus on the following points: (1) they should target mechanisms to achieve efficient glycemic control with a safe weight loss profile."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D000085002",
        "entry_name": "Glycemic Control"
      },
      {
        "db": "MESH",
        "id": "D015431",
        "entry_name": "Weight Loss"
      }
    ]
  },
  {
    "Index": "67",
    "Results": [
      {
        "bel_statement": "path(MESH:D050110) decreases path(MESH:D003920)",
        "evidence": "Bariatric surgery has provided sensational improvements for many patients; however, significant relapse after six months has been reported."
      },
      {
        "bel_statement": "path(MESH:D050110) decreases path(MESH:D008659)",
        "evidence": "The clinical and laboratory findings from this and other ongoing trials will no doubt contribute to advancing our therapeutic approaches to the management of diabetes and other metabolic disorders (Table 4)."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D050110",
        "entry_name": "Bariatric Surgery"
      },
      {
        "db": "EFO",
        "id": "0004952",
        "entry_name": "disease recurrence"
      },
      {
        "db": "MESH",
        "id": "D012106",
        "entry_name": "Research"
      },
      {
        "db": "DOID",
        "id": "DOID:9970",
        "entry_name": "obesity"
      },
      {
        "db": "MESH",
        "id": "D001769",
        "entry_name": "Blood"
      },
      {
        "db": "MESH",
        "id": "D001132",
        "entry_name": "Arm"
      },
      {
        "db": "MESH",
        "id": "D013514",
        "entry_name": "Surgical Procedures, Operative"
      },
      {
        "db": "EFO",
        "id": "0009642",
        "entry_name": "follow-up"
      },
      {
        "db": "MESH",
        "id": "D007753",
        "entry_name": "Laboratories"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "MESH",
        "id": "D020501",
        "entry_name": "Tables"
      }
    ]
  },
  {
    "Index": "68",
    "Results": [],
    "annotations": [
      {
        "db": "EFO",
        "id": "0001796",
        "entry_name": "published"
      },
      {
        "db": "MESH",
        "id": "D019532",
        "entry_name": "Map"
      }
    ]
  },
  {
    "Index": "69",
    "Results": [],
    "annotations": []
  },
  {
    "Index": "70",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003210",
        "entry_name": "Concept Formation"
      },
      {
        "db": "MESH",
        "id": "D012984",
        "entry_name": "Software"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48341",
        "entry_name": "dimethoxymethane"
      },
      {
        "db": "MESH",
        "id": "D066289",
        "entry_name": "Data Curation"
      },
      {
        "db": "MESH",
        "id": "D014956",
        "entry_name": "Writing"
      },
      {
        "db": "MESH",
        "id": "D014956",
        "entry_name": "Writing"
      },
      {
        "db": "MESH",
        "id": "D016454",
        "entry_name": "Review"
      },
      {
        "db": "DOID",
        "id": "DOID:1996",
        "entry_name": "rectum adenocarcinoma"
      },
      {
        "db": "EFO",
        "id": "0001796",
        "entry_name": "published"
      },
      {
        "db": "MESH",
        "id": "D020486",
        "entry_name": "Manuscript"
      }
    ]
  },
  {
    "Index": "71",
    "Results": [],
    "annotations": [
      {
        "db": "DOID",
        "id": "DOID:1996",
        "entry_name": "rectum adenocarcinoma"
      },
      {
        "db": "MESH",
        "id": "D020486",
        "entry_name": "Manuscript"
      },
      {
        "db": "HGNC",
        "id": "10522",
        "entry_name": "ACSM3"
      },
      {
        "db": "MESH",
        "id": "D054555",
        "entry_name": "National Heart, Lung, and Blood Institute (U.S.)"
      },
      {
        "db": "MESH",
        "id": "D054584",
        "entry_name": "National Institute of Dental and Craniofacial Research (U.S.)"
      }
    ]
  },
  {
    "Index": "72",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D028744",
        "entry_name": "Ethics Committees, Research"
      }
    ]
  },
  {
    "Index": "73",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D007258",
        "entry_name": "Informed Consent"
      }
    ]
  },
  {
    "Index": "74",
    "Results": [],
    "annotations": []
  },
  {
    "Index": "75",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D016265",
        "entry_name": "Conflict of Interest"
      }
    ]
  },
  {
    "Index": "76",
    "Results": [
      {
        "bel_statement": "a(CHEBI:34922) directlyDecreases act(p(HGNC:11037))",
        "evidence": "Sodium-glucose co-transporter type 2 (SGLT2) inhibitor pathway."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D027981",
        "entry_name": "Symporters"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      },
      {
        "db": "MESH",
        "id": "D027981",
        "entry_name": "Symporters"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      }
    ]
  },
  {
    "Index": "77",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "C069856",
        "entry_name": "TimeLine"
      },
      {
        "db": "MESH",
        "id": "D000076722",
        "entry_name": "Drug Development"
      }
    ]
  },
  {
    "Index": "78",
    "Results": [],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "79",
    "Results": [
      {
        "bel_statement": "a(MESH:D002681) association a(MESH:D007194)",
        "evidence": "1 China 116.4 India 134.3"
      },
      {
        "bel_statement": "a(MESH:D007194) association a(MESH:D002681)",
        "evidence": "2 India 77 China 119.8"
      },
      {
        "bel_statement": "a(MESH:D010154) association a(MESH:D008800)",
        "evidence": "4 Pakistan 19.4 Mexico 21.8"
      },
      {
        "bel_statement": "a(MESH:D001938) association a(MESH:D001938)",
        "evidence": "5 Brazil 16.8 Brazil 20.3"
      },
      {
        "bel_statement": "a(MESH:D008800) association a(MESH:D004534)",
        "evidence": "6 Mexico 12.8 Egypt 16.7"
      },
      {
        "bel_statement": "a(MESH:D007214) association a(MESH:D007214)",
        "evidence": "7 Indonesia 10.7 Indonesia 16.7"
      },
      {
        "bel_statement": "a(MESH:D010154) association a(MESH:D001459)",
        "evidence": "8 Pakistan 16.1 Bangladesh 13.7"
      }
    ],
    "annotations": [
      {
        "db": "HGNC",
        "id": "11908",
        "entry_name": "TNFRSF11A"
      },
      {
        "db": "MESH",
        "id": "D002681",
        "entry_name": "China"
      },
      {
        "db": "MESH",
        "id": "D007194",
        "entry_name": "India"
      },
      {
        "db": "MESH",
        "id": "D007194",
        "entry_name": "India"
      },
      {
        "db": "MESH",
        "id": "D002681",
        "entry_name": "China"
      },
      {
        "db": "MESH",
        "id": "D010154",
        "entry_name": "Pakistan"
      },
      {
        "db": "MESH",
        "id": "D008800",
        "entry_name": "Mexico"
      },
      {
        "db": "MESH",
        "id": "D001938",
        "entry_name": "Brazil"
      },
      {
        "db": "MESH",
        "id": "D001938",
        "entry_name": "Brazil"
      },
      {
        "db": "MESH",
        "id": "D008800",
        "entry_name": "Mexico"
      },
      {
        "db": "MESH",
        "id": "D004534",
        "entry_name": "Egypt"
      },
      {
        "db": "MESH",
        "id": "D007214",
        "entry_name": "Indonesia"
      },
      {
        "db": "MESH",
        "id": "D007214",
        "entry_name": "Indonesia"
      },
      {
        "db": "MESH",
        "id": "D005858",
        "entry_name": "Germany"
      },
      {
        "db": "MESH",
        "id": "D010154",
        "entry_name": "Pakistan"
      },
      {
        "db": "HGNC",
        "id": "5872",
        "entry_name": "IGLL3P"
      },
      {
        "db": "MESH",
        "id": "D004534",
        "entry_name": "Egypt"
      },
      {
        "db": "MESH",
        "id": "D001459",
        "entry_name": "Bangladesh"
      },
      {
        "db": "MESH",
        "id": "D001459",
        "entry_name": "Bangladesh"
      },
      {
        "db": "MESH",
        "id": "D014421",
        "entry_name": "Turkey"
      }
    ]
  },
  {
    "Index": "80",
    "Results": [
      {
        "bel_statement": "a(CHEBI:35526) isA a(CHEBI:23888)",
        "evidence": "New anti-diabetic drugs in the drug discovery pipeline."
      },
      {
        "bel_statement": "a(CHEBI:23888) increases path(MESH:D055808)",
        "evidence": "New anti-diabetic drugs in the drug discovery pipeline."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D055808",
        "entry_name": "Drug Discovery"
      }
    ]
  },
  {
    "Index": "81",
    "Results": [
      {
        "bel_statement": "a(CHEBI:78425) increases a(MESH:D004763)",
        "evidence": "Albiglutide GlaxoSmithKline Glucagon-like peptide (GLP) 1 agonist Once weekly for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:78425) increases path(MESH:D003920)",
        "evidence": "Albiglutide GlaxoSmithKline Glucagon-like peptide (GLP) 1 agonist Once weekly for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C542437) increases complex(FPLX:PPAR, FPLX:PPAR)",
        "evidence": "Aleglitazar Roche Dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma activation Cardiovascular risk reduction in type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C542437) increases path(MESH:D003920)",
        "evidence": "Aleglitazar Roche Dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma activation Cardiovascular risk reduction in type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:72323) increases a(CHEBI:68612)",
        "evidence": "Alogliptin, Alogliptin and pioglitazone, Alogliptin and metformin Takeda Pharmaceuticals and Furiex Pharmaceuticals DPP-4 inhibitor Oral treatment of type 2 diabetes, individually and in two fixed-dose combinations"
      },
      {
        "bel_statement": "a(CHEBI:72323) increases path(MESH:D003920)",
        "evidence": "Alogliptin, Alogliptin and pioglitazone, Alogliptin and metformin Takeda Pharmaceuticals and Furiex Pharmaceuticals DPP-4 inhibitor Oral treatment of type 2 diabetes, individually and in two fixed-dose combinations"
      },
      {
        "bel_statement": "a(CHEBI:135810) decreases act(GO:0038023)",
        "evidence": "Atrasentan AbbVie Selective endothelin-A receptor antagonist Oral once-daily treatment for diabetic nephropathy"
      },
      {
        "bel_statement": "a(CHEBI:135810) decreases path(MESH:D003920)",
        "evidence": "Atrasentan AbbVie Selective endothelin-A receptor antagonist Oral once-daily treatment for diabetic nephropathy"
      },
      {
        "bel_statement": "a(MESH:C555680) increases a(MESH:D004763)",
        "evidence": "Dulaglutide (LY2189265) Eli Lilly GLP-1 analog Once weekly for type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C555680) increases path(MESH:D003920)",
        "evidence": "Dulaglutide (LY2189265) Eli Lilly GLP-1 analog Once weekly for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:82720) decreases a(FPLX:SLC2A)",
        "evidence": "Empagliflozin (BI10773) Boehringer Ingelheim and Eli Lilly Sodium dependent glucose transporter 2 (SGLT2) inhibitor Oral treatment for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:82720) decreases path(MESH:D003920)",
        "evidence": "Empagliflozin (BI10773) Boehringer Ingelheim and Eli Lilly Sodium dependent glucose transporter 2 (SGLT2) inhibitor Oral treatment for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:188719) decreases a(FPLX:SLC2A)",
        "evidence": "Ertugliflozin (MK-8835; PF-04971729) Merck & Co., licensed from Pfizer SGLT2 inhibitor Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:188719) decreases path(MESH:D003920)",
        "evidence": "Ertugliflozin (MK-8835; PF-04971729) Merck & Co., licensed from Pfizer SGLT2 inhibitor Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:177451) increases act(FPLX:GPCR)",
        "evidence": "Fasiglifam (TAK-875) Takeda G-protein-coupled receptor (GPCR) 40 agonist Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:177451) increases path(MESH:D003920)",
        "evidence": "Fasiglifam (TAK-875) Takeda G-protein-coupled receptor (GPCR) 40 agonist Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85078) decreases a(FPLX:SLC2A)",
        "evidence": "Forxiga (dapagliflozin) Bristol Myers Squibb and AstraZeneca SGLT2 inhibitor Once-daily tablets for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85078) decreases path(MESH:D003920)",
        "evidence": "Forxiga (dapagliflozin) Bristol Myers Squibb and AstraZeneca SGLT2 inhibitor Once-daily tablets for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C000613158) increases a(MESH:D004359)",
        "evidence": "IDegLira (NN9068) Novo Nordisk Combination drug therapy Type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C000613158) increases path(MESH:D003920)",
        "evidence": "IDegLira (NN9068) Novo Nordisk Combination drug therapy Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:73274) decreases a(FPLX:SLC2A)",
        "evidence": "Invokana (canagliflozin) Johnson & Johnson SGLT2 inhibitor Once-daily tablets for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:73274) decreases path(MESH:D003920)",
        "evidence": "Invokana (canagliflozin) Johnson & Johnson SGLT2 inhibitor Once-daily tablets for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134724) decreases a(FPLX:SLC2A)",
        "evidence": "Ipragliflozin L-proline (ASP1941) Astellas, MSD, and Kotobuki Pharmaceutical SGLT2 inhibitor Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134724) decreases path(MESH:D003920)",
        "evidence": "Ipragliflozin L-proline (ASP1941) Astellas, MSD, and Kotobuki Pharmaceutical SGLT2 inhibitor Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134725) decreases a(FPLX:SLC2A)",
        "evidence": "Luseogliflozin hydrate (TS-071) Taisho Pharmaceutical SGLT2 inhibitor Once-daily for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134725) decreases path(MESH:D003920)",
        "evidence": "Luseogliflozin hydrate (TS-071) Taisho Pharmaceutical SGLT2 inhibitor Once-daily for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85662) increases a(MESH:D004359)",
        "evidence": "LixiLan (lixisenatide+ insulin glargine) Sanofi; lixisenatide Combination drug therapy Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85662) increases path(MESH:D003920)",
        "evidence": "LixiLan (lixisenatide+ insulin glargine) Sanofi; lixisenatide Combination drug therapy Type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85662) increases a(MESH:D004763)",
        "evidence": "Lyxumia (lixisenatide) Sanofi; licensed from Zealand Pharma GLP-1 agonist Once-daily for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:85662) increases path(MESH:D003920)",
        "evidence": "Lyxumia (lixisenatide) Sanofi; licensed from Zealand Pharma GLP-1 agonist Once-daily for type 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C587357) increases a(HGNC:6081)",
        "evidence": "LY2605541 (basal insulin peglispro) Eli Lilly Basal insulin analog Type 1 and 2 diabetes"
      },
      {
        "bel_statement": "a(MESH:C587357) increases path(MESH:D003920)",
        "evidence": "LY2605541 (basal insulin peglispro) Eli Lilly Basal insulin analog Type 1 and 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134735) increases a(CHEBI:68612)",
        "evidence": "Omarigliptin (MK-3102) Merck & Co. DPP-4 inhibitor Once-weekly for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134735) increases path(MESH:D003920)",
        "evidence": "Omarigliptin (MK-3102) Merck & Co. DPP-4 inhibitor Once-weekly for adults with type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:167574) increases a(MESH:D004763)",
        "evidence": "Semaglutide (NN9535) Novo Nordisk GLP-1 analog Once-weekly for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:167574) increases path(MESH:D003920)",
        "evidence": "Semaglutide (NN9535) Novo Nordisk GLP-1 analog Once-weekly for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134715) increases a(CHEBI:68612)",
        "evidence": "SYR-472 (trelagliptin succinate) Takeda Pharmaceuticals and Furiex Pharmaceuticals DPP-4 inhibitor Once-weekly oral treatment for type 2 diabetes"
      },
      {
        "bel_statement": "a(CHEBI:134715) increases path(MESH:D003920)",
        "evidence": "SYR-472 (trelagliptin succinate) Takeda Pharmaceuticals and Furiex Pharmaceuticals DPP-4 inhibitor Once-weekly oral treatment for type 2 diabetes"
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D009275",
        "entry_name": "Names"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "MESH",
        "id": "D000328",
        "entry_name": "Adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:78425",
        "entry_name": "albiglutide"
      },
      {
        "db": "MESH",
        "id": "D004763",
        "entry_name": "Glucagon-Like Peptides"
      },
      {
        "db": "HGNC",
        "id": "24650",
        "entry_name": "EHMT1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "C542437",
        "entry_name": "aleglitazar"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "FPLX",
        "id": "PPAR",
        "entry_name": "PPAR"
      },
      {
        "db": "MESH",
        "id": "D012306",
        "entry_name": "Risk"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:72323",
        "entry_name": "alogliptin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:72323",
        "entry_name": "alogliptin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:8228",
        "entry_name": "pioglitazone"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:72323",
        "entry_name": "alogliptin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:6801",
        "entry_name": "metformin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:68612",
        "entry_name": "EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:135810",
        "entry_name": "atrasentan"
      },
      {
        "db": "GO",
        "id": "GO:0038023",
        "entry_name": "signaling receptor activity"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48706",
        "entry_name": "antagonist"
      },
      {
        "db": "HGNC",
        "id": "2875",
        "entry_name": "DIANPH"
      },
      {
        "db": "MESH",
        "id": "C555680",
        "entry_name": "dulaglutide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:82720",
        "entry_name": "empagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:82720",
        "entry_name": "empagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52634",
        "entry_name": "sodium-23 atom"
      },
      {
        "db": "FPLX",
        "id": "SLC2A",
        "entry_name": "SLC2A"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:188719",
        "entry_name": "Ertugliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:177451",
        "entry_name": "Fasiglifam"
      },
      {
        "db": "MESH",
        "id": "C557331",
        "entry_name": "TAK-875"
      },
      {
        "db": "MESH",
        "id": "D043562",
        "entry_name": "Receptors, G-Protein-Coupled"
      },
      {
        "db": "FPLX",
        "id": "GPCR",
        "entry_name": "GPCR"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D061267",
        "entry_name": "Insulin Aspart"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85079",
        "entry_name": "dapagliflozin propanediol monohydrate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85078",
        "entry_name": "dapagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D013607",
        "entry_name": "Tablets"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "C000613158",
        "entry_name": "IDegLira"
      },
      {
        "db": "MESH",
        "id": "D004359",
        "entry_name": "Drug Therapy, Combination"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73272",
        "entry_name": "canagliflozin hydrate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73274",
        "entry_name": "canagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D013607",
        "entry_name": "Tablets"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:134724",
        "entry_name": "ipragliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17203",
        "entry_name": "L-proline"
      },
      {
        "db": "HGNC",
        "id": "7322",
        "entry_name": "MSD"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:134725",
        "entry_name": "luseogliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:35505",
        "entry_name": "hydrate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73273",
        "entry_name": "sodium-glucose transport protein subtype 2 inhibitor"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D000069036",
        "entry_name": "Insulin Glargine"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85662",
        "entry_name": "lixisenatide"
      },
      {
        "db": "MESH",
        "id": "D004359",
        "entry_name": "Drug Therapy, Combination"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85662",
        "entry_name": "lixisenatide"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85662",
        "entry_name": "lixisenatide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "C587357",
        "entry_name": "LY2605541"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D000069036",
        "entry_name": "Insulin Glargine"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:134735",
        "entry_name": "omarigliptin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17245",
        "entry_name": "carbon monoxide"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:68612",
        "entry_name": "EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor"
      },
      {
        "db": "EFO",
        "id": "0001272",
        "entry_name": "adult"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "C571886",
        "entry_name": "insulin degludec"
      },
      {
        "db": "MESH",
        "id": "D061267",
        "entry_name": "Insulin Aspart"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D061267",
        "entry_name": "Insulin Aspart"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:167574",
        "entry_name": "semaglutide"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:167574",
        "entry_name": "semaglutide"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:134715",
        "entry_name": "trelagliptin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:26806",
        "entry_name": "succinate"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:52217",
        "entry_name": "pharmaceutical"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:68612",
        "entry_name": "EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "C571886",
        "entry_name": "insulin degludec"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D000069036",
        "entry_name": "Insulin Glargine"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      }
    ]
  },
  {
    "Index": "82",
    "Results": [
      {
        "bel_statement": "a(CHEBI:35526) decreases path(MESH:D003920)",
        "evidence": "List of new anti-diabetic drugs targeting molecular pathways implicated in diabetes and CVD."
      },
      {
        "bel_statement": "a(CHEBI:35526) decreases path(MESH:D002318)",
        "evidence": "List of new anti-diabetic drugs targeting molecular pathways implicated in diabetes and CVD."
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:35526",
        "entry_name": "hypoglycemic agent"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D002318",
        "entry_name": "Cardiovascular Diseases"
      }
    ]
  },
  {
    "Index": "83",
    "Results": [
      {
        "bel_statement": "p(HGNC:HSD11B1) decreases a(CHEBI:cortisol)",
        "evidence": "11beta-HSD1(hydroxysteroid dehydrogenase) Blocking cortisol"
      },
      {
        "bel_statement": "p(HGNC:GPR119) increases bp(GO:\"cAMP-mediated signaling\")",
        "evidence": "G protein-coupled receptor (GPR119) Increases cAMP signaling"
      },
      {
        "bel_statement": "p(HGNC:GPBAR1) increases a(CHEBI:\"3',5'-cyclic AMP\")",
        "evidence": "TGR5 (bile-acid activated GPCR) cAMP accumulation and enhances GLP-1 secretion (intestine), anti-inflammatory effect (liver)"
      },
      {
        "bel_statement": "p(HGNC:GPBAR1) increases bp(GO:secretion)",
        "evidence": "TGR5 (bile-acid activated GPCR) cAMP accumulation and enhances GLP-1 secretion (intestine), anti-inflammatory effect (liver)"
      },
      {
        "bel_statement": "p(HGNC:SIRT1) increases bp(GO:\"glucose homeostasis\")",
        "evidence": "SIRT1 Improves insulin sensitivity, increases glucose homeostasis, increases mitochondrial capacity"
      },
      {
        "bel_statement": "p(HGNC:SLC5A2) increases bp(GO:\"glucose homeostasis\")",
        "evidence": "SGLT-2 Increases kidney-dependent glucose homeostasis"
      },
      {
        "bel_statement": "p(HGNC:FFAR1) increases bp(GO:secretion)",
        "evidence": "GPR40 Increases incretin secretion, improves glucose tolerance"
      },
      {
        "bel_statement": "p(HGNC:PPARG) increases bp(GO:\"glucose homeostasis\")",
        "evidence": "PPAR-gamma Improves serum lipid profile, glucose homeostasis, insulin sensitivity, reduces inflammation and weight gain"
      },
      {
        "bel_statement": "p(HGNC:PPARG) decreases bp(GO:\"inflammatory response\")",
        "evidence": "PPAR-gamma Improves serum lipid profile, glucose homeostasis, insulin sensitivity, reduces inflammation and weight gain"
      },
      {
        "bel_statement": "p(HGNC:MATK) decreases bp(GO:\"apoptotic process\")",
        "evidence": "Tyrosine Kinase Reduces beta cell apoptosis, enhances insulin secretion, increases beta cell survival, reduces insulin resistance"
      },
      {
        "bel_statement": "p(HGNC:MATK) increases bp(GO:\"insulin secretion\")",
        "evidence": "Tyrosine Kinase Reduces beta cell apoptosis, enhances insulin secretion, increases beta cell survival, reduces insulin resistance"
      },
      {
        "bel_statement": "p(HGNC:IDE) decreases a(CHEBI:thiol)",
        "evidence": "Insulin degrading enzyme (IDE) Thiol zinc-metalloendopeptidase that cleaves small proteins of diverse sequence"
      },
      {
        "bel_statement": "p(HGNC:SLC27A5) increases a(CHEBI:\"long-chain fatty acid\")",
        "evidence": "FATP5 Enhances the uptake of long-chain and very long-chain fatty acids into the cells"
      },
      {
        "bel_statement": "p(HGNC:ADIPOQ) decreases path(MESH:Obesity)",
        "evidence": "Decreased adiponectin levels are thought to play a central role in the development of type 2 diabetes and obesity"
      },
      {
        "bel_statement": "p(HGNC:ADIPOQ) decreases path(MESH:\"Diabetes Mellitus\")",
        "evidence": "Decreased adiponectin levels are thought to play a central role in the development of type 2 diabetes and obesity"
      },
      {
        "bel_statement": "p(HGNC:SLC2A4) increases bp(GO:exocytosis)",
        "evidence": "Triggering the canonical PI3K-AKT pathway is essential and ample to activate exocytosis of GLUT4 storage vesicles to the plasma membrane"
      },
      {
        "bel_statement": "p(HGNC:SLC2A4) increases bp(GO:\"glucose homeostasis\")",
        "evidence": "Rutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice"
      },
      {
        "bel_statement": "p(HGNC:PPARGC1A) decreases path(MESH:\"Diabetes Mellitus\")",
        "evidence": "Reduction in PGC-1alpha triggers insulin resistance and ultimately causes diabetes"
      }
    ],
    "annotations": [
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "HGNC",
        "id": "19071",
        "entry_name": "ALYREF"
      },
      {
        "db": "HGNC",
        "id": "5208",
        "entry_name": "HSD11B1"
      },
      {
        "db": "MESH",
        "id": "D006913",
        "entry_name": "Hydroxysteroid Dehydrogenases"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17650",
        "entry_name": "cortisol"
      },
      {
        "db": "MESH",
        "id": "C552933",
        "entry_name": "INCB 13739"
      },
      {
        "db": "MESH",
        "id": "C585925",
        "entry_name": "MK-0916"
      },
      {
        "db": "MESH",
        "id": "D043562",
        "entry_name": "Receptors, G-Protein-Coupled"
      },
      {
        "db": "HGNC",
        "id": "19060",
        "entry_name": "GPR119"
      },
      {
        "db": "GO",
        "id": "GO:0019933",
        "entry_name": "cAMP-mediated signaling"
      },
      {
        "db": "MESH",
        "id": "C000608114",
        "entry_name": "MBX-2982"
      },
      {
        "db": "HGNC",
        "id": "19680",
        "entry_name": "GPBAR1"
      },
      {
        "db": "FPLX",
        "id": "GPCR",
        "entry_name": "GPCR"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17489",
        "entry_name": "3',5'-cyclic AMP"
      },
      {
        "db": "HGNC",
        "id": "37245",
        "entry_name": "ZGLP1"
      },
      {
        "db": "GO",
        "id": "GO:0046903",
        "entry_name": "secretion"
      },
      {
        "db": "MESH",
        "id": "D007422",
        "entry_name": "Intestines"
      },
      {
        "db": "MESH",
        "id": "D008099",
        "entry_name": "Liver"
      },
      {
        "db": "HGNC",
        "id": "14929",
        "entry_name": "SIRT1"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "MESH",
        "id": "C584666",
        "entry_name": "SRT2104"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:27881",
        "entry_name": "resveratrol"
      },
      {
        "db": "HGNC",
        "id": "11037",
        "entry_name": "SLC5A2"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:85078",
        "entry_name": "dapagliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:73274",
        "entry_name": "canagliflozin"
      },
      {
        "db": "MESH",
        "id": "C516973",
        "entry_name": "sergliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:134724",
        "entry_name": "ipragliflozin"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:82720",
        "entry_name": "empagliflozin"
      },
      {
        "db": "HGNC",
        "id": "4498",
        "entry_name": "FFAR1"
      },
      {
        "db": "MESH",
        "id": "D054795",
        "entry_name": "Incretins"
      },
      {
        "db": "GO",
        "id": "GO:0046903",
        "entry_name": "secretion"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "HGNC",
        "id": "9236",
        "entry_name": "PPARG"
      },
      {
        "db": "MESH",
        "id": "D044967",
        "entry_name": "Serum"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:18059",
        "entry_name": "lipid"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "GO",
        "id": "GO:0006954",
        "entry_name": "inflammatory response"
      },
      {
        "db": "MESH",
        "id": "D015430",
        "entry_name": "Weight Gain"
      },
      {
        "db": "MESH",
        "id": "C542437",
        "entry_name": "aleglitazar"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50864",
        "entry_name": "insulin-sensitizing drug"
      },
      {
        "db": "HGNC",
        "id": "6906",
        "entry_name": "MATK"
      },
      {
        "db": "GO",
        "id": "GO:0006915",
        "entry_name": "apoptotic process"
      },
      {
        "db": "GO",
        "id": "GO:0030073",
        "entry_name": "insulin secretion"
      },
      {
        "db": "MESH",
        "id": "D013534",
        "entry_name": "Survival"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:45783",
        "entry_name": "imatinib"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:38940",
        "entry_name": "sunitinib"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:49375",
        "entry_name": "dasatinib (anhydrous)"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:50924",
        "entry_name": "sorafenib"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:114785",
        "entry_name": "erlotinib"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      },
      {
        "db": "GO",
        "id": "GO:0046323",
        "entry_name": "glucose import"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:3181",
        "entry_name": "bromocriptine"
      },
      {
        "db": "HGNC",
        "id": "5381",
        "entry_name": "IDE"
      },
      {
        "db": "HGNC",
        "id": "5381",
        "entry_name": "IDE"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:29256",
        "entry_name": "thiol"
      },
      {
        "db": "MESH",
        "id": "C000607809",
        "entry_name": "BDM44768"
      },
      {
        "db": "HGNC",
        "id": "10999",
        "entry_name": "SLC27A5"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15904",
        "entry_name": "long-chain fatty acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:16755",
        "entry_name": "chenodeoxycholic acid"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:9907",
        "entry_name": "ursodeoxycholic acid"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:87631",
        "entry_name": "statin"
      },
      {
        "db": "MESH",
        "id": "D008052",
        "entry_name": "Lipid Metabolism, Inborn Errors"
      },
      {
        "db": "HGNC",
        "id": "13633",
        "entry_name": "ADIPOQ"
      },
      {
        "db": "HP",
        "id": "HP:0030685",
        "entry_name": "Decreased adiponectin level"
      },
      {
        "db": "HP",
        "id": "HP:0030645",
        "entry_name": "Central"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D009765",
        "entry_name": "Obesity"
      },
      {
        "db": "MESH",
        "id": "C585113",
        "entry_name": "AdipoRon"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:25367",
        "entry_name": "molecule"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      },
      {
        "db": "HGNC",
        "id": "24040",
        "entry_name": "ADIPOR1"
      },
      {
        "db": "HGNC",
        "id": "24041",
        "entry_name": "ADIPOR2"
      },
      {
        "db": "MESH",
        "id": "D054419",
        "entry_name": "Receptors, Adiponectin"
      },
      {
        "db": "HGNC",
        "id": "11009",
        "entry_name": "SLC2A4"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:34922",
        "entry_name": "picloram"
      },
      {
        "db": "GO",
        "id": "GO:0006887",
        "entry_name": "exocytosis"
      },
      {
        "db": "HGNC",
        "id": "11009",
        "entry_name": "SLC2A4"
      },
      {
        "db": "GO",
        "id": "GO:0005886",
        "entry_name": "plasma membrane"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:15738",
        "entry_name": "staurosporine"
      },
      {
        "db": "EFO",
        "id": "0004024",
        "entry_name": "translocation"
      },
      {
        "db": "GO",
        "id": "GO:0046323",
        "entry_name": "glucose import"
      },
      {
        "db": "FPLX",
        "id": "AMPK",
        "entry_name": "AMPK"
      },
      {
        "db": "HGNC",
        "id": "11009",
        "entry_name": "SLC2A4"
      },
      {
        "db": "EFO",
        "id": "0004024",
        "entry_name": "translocation"
      },
      {
        "db": "GO",
        "id": "GO:0042593",
        "entry_name": "glucose homeostasis"
      },
      {
        "db": "HGNC",
        "id": "7094",
        "entry_name": "MICE"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "HGNC",
        "id": "9237",
        "entry_name": "PPARGC1A"
      },
      {
        "db": "EFO",
        "id": "0002614",
        "entry_name": "insulin resistance"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:48705",
        "entry_name": "agonist"
      }
    ]
  },
  {
    "Index": "84",
    "Results": [
      {
        "bel_statement": "path(MESH:D003920) increases a(CHEBI:17234)",
        "evidence": "Diabetes mellitus is a complex metabolic disruption characterized by chronic hyperglycemia due to deficiencies in insulin production, its systemic release and action, and resistance."
      },
      {
        "bel_statement": "a(CHEBI:17234) increases path(MESH:D003920)",
        "evidence": "We listed promising therapeutic targets for treatment of T2DM, most of them involving improvements in glucose tolerance."
      }
    ],
    "annotations": [
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "HP",
        "id": "HP:0011010",
        "entry_name": "Chronic"
      },
      {
        "db": "MESH",
        "id": "D006943",
        "entry_name": "Hyperglycemia"
      },
      {
        "db": "HGNC",
        "id": "6081",
        "entry_name": "INS"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:5133",
        "entry_name": "fluthiacet-methyl"
      },
      {
        "db": "EFO",
        "id": "0010247",
        "entry_name": "incident"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D004798",
        "entry_name": "Enzymes"
      },
      {
        "db": "MESH",
        "id": "D032882",
        "entry_name": "Comprehension"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:17234",
        "entry_name": "glucose"
      },
      {
        "db": "CHEBI",
        "id": "CHEBI:23888",
        "entry_name": "drug"
      },
      {
        "db": "MESH",
        "id": "D008659",
        "entry_name": "Metabolic Diseases"
      },
      {
        "db": "MESH",
        "id": "D003920",
        "entry_name": "Diabetes Mellitus"
      },
      {
        "db": "MESH",
        "id": "D013812",
        "entry_name": "Therapeutics"
      }
    ]
  }
]